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This dissertation research is focused on mechanistic studies of early stage, non-
mammalian isoprenoid biosynthesis enzymes, toward the development of selective 
inhibitors that will target serious human pathogens including Mycobacterium tuberculosis 
and Plasmodium falciparum. A major focus of this research has been toward elucidating 
the random sequential, preferred order mechanism of the first enzyme in the pathway, 1-
deoxy-D-xylulose 5-phosphate (DXP) synthase, an unprecedented enzyme in the 
thiamine diphosphate-dependent family of enzymes. Understanding this mechanism has 
been integral for selective inhibitor design and we have demonstrated, for the first time, 
selective inhibition of E. coli DXP synthase by butylacetylphosphonate (BAP). Further, 
selective inhibition is conserved in Y. pestis, S. enterica, and M. tuberculosis. This 
discovery is significant because DXP synthase is underdeveloped as a drug target and 
few inhibitors of this enzyme exist. 
Subsequently, BAP was evaluated as an antimicrobial agent against E. coli. 
Results of these studies demonstrated DXP synthase as an intracellular target of BAP 
showed that antimicrobial activity is dramatically enhanced in combination with several 
established antibiotic classes. These results indicate that BAP has the potential to be 
further developed as a broad spectrum antibiotic. With antibiotic resistance on the rise, 
this could have great impact in the treatment of resistant bacterial infections.  
In addition to mechanistic studies of E. coli DXP synthase, initial studies were 
carried out to understand the mechanism of the M. tuberculosis enzyme (Dxs1), as 
homology modeling (Jürgen Bosch, Ph.D.) suggested differences in the active site of 




studies performed during the course of this research demonstrate interesting differences 
in the active site of Dxs1 near the cofactor binding site. This is an important 
consideration for inhibitor development and will contribute to the efforts of those in the 
field targeting DXP synthase.  
DXP reductoisomerase (IspC), the second enzyme in the pathway, was also 
targeted. In order to overcome poor pharmacokinetics of fosmidomycin, N-acetyl 
fosfoxacin analogs and a FR900098 phosphonamidate prodrug were biochemically 
evaluated as inhibitors of E. coli IspC. Acetohydroxamic acid (AHA) exhibited enhanced 
activity against IspC in the presence of phosphate. The activated FR900098 
phosphonamidate prodrug also exhibited inhibitory activity against IspC, and displayed 
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CHAPTER 1: INTRODUCTION 
 
1.1 Antibiotics and antimicrobial resistance. 
Antibiotics are one of the pillars of modern medicine. They target a variety of 
essential biosynthetic pathways in bacteria and human pathogens. These targets are either 
different or non-existent in humans, which make antibiotics relatively nontoxic as drugs 
(1)
. Antibiotic resistance can occur through a number of different mechanisms (Figure 1-
1). For example, a large family of efflux pumps can eject an antibiotic from within the 
cell, effectively lowering intracellular concentration, as observed in linezolid and the 
AcrABTolC multidrug pump 
(2, 3)
. This mechanism of resistance is one of the most 
common and occurs with most antibiotic classes 
(2, 3)
. In another example, tetracycline 
efflux can occur where tetracycline itself upregulates the transcription of efflux pump, 
TetA(B) 
(2, 3)
. Immunity and bypass can also occur; either the antibiotic or its target 
becomes bound to a protein that prevents interaction between the antibiotic and target 
(2, 
3)
.  In particular, ribosomal protection proteins (RPPS) that are widely distributed in both 
Gram-negative and Gram-positive bacteria, mediate tetracycline resistance by dislodging 
tetracycline from the ribosome and increase the apparent dissociation constant (Kd) of 
tetracycline binding 
(4)
. Microorganisms can also become resistant when there is a 
mutation in the antibiotic target itself 
(2, 3)
. For instance, under normal circumstances 
vancomycin binds with high affinity to the D-Ala-D-Ala C-terminus of the N-
acetylmuramyl-pentapeptide and prevents cell wall biosynthesis 
(5)
. However, bacteria are 
able to modify the target of vancomycin to D-Ala-D-lactate, and this results in a ~1000 







Figure 1-1. Mechanisms of antibiotic resistance. 
 
Finally, enzyme-catalyzed inactivation of an antibiotic is the largest and most 
specific form of resistance 
(2, 3)
. For example, beta-lactam antibiotics, such as penicillin, 
can undergo ring-opening, catalyzed by beta-lactamase enzymes, and this deactivates the 
molecule’s antibacterial properties 
(6)
. The 1940s truly were the “Golden Age” of 
antibiotic discovery, during which many of the antibiotics still used today were deployed 
(2)
 (Table 1-1). However, the more an antibiotic is used, the higher the incidence of 
resistance against that antibiotic becomes in response to selective pressure. To date, 
clinically relevant resistance has been observed for almost every antibiotic class 
established 
(2)
. This is especially concerning in light of the 40 year innovation gap, 
following the “Golden Age” of antibiotic discovery during which no new structural 
classes of antibiotics were developed 
(2)
. The Golden Age took place during World War 
II; there was a large push to develop antibiotics in order to provide support to troops, as 
















































quinolones ciprofloxacin 1961 1968 1968 DNA synthesis broad spectrum 








lipopeptides daptomycin 1986 2003 1987 cell membrane Gram positive 
fidaxomicin 
 




diarylquinolone bedaquiline 1997 2012 2006 F1F0-ATPase 
Mycobacterium 
tuberculosis 




Another reason is that the pharmaceutical industry has cut back antibiotic research 
programs; antibiotic research is less profitable over time compared to other therapies 
because antibiotics are typically prescribed for short course treatment, and are not 
generally prescribed for chronic illness. Typical antibiotic regimens vary depending on 
the type of infection. For example, treatment of an acute ear infection involves a seven to 
ten day amoxicillin course 
(9)
, while the treatment regimen for an active tuberculosis 






Areas of the world most impacted by infectious disease, such as tuberculosis and malaria, 
include sub-Saharan Africa and parts of Asia, but accessibility to treatments is not always 
possible at these locations 
(11)
. This specifically impacts antibiotic discovery because 
there is no “for profit” demand in these developing countries. Although the Food and 
Drug Administration has implemented a number of programs to entice industry 
development of antibiotic research programs 
(12)
, the well is drying up. To date, only two 
new antibiotics have been approved in the past 5 years for the treatment of multidrug-
resistant gram-negative bacilli and the number of antibiotics approved annually continues 
to decline 
(13)
. Bedaquiline (diarylquinoline) is the most recent antibiotic approved by the 
FDA in December of 2012, specifically for the treatment of multi-drug resistant 
tuberculosis infection 
(14)
. This antibiotic has a novel mechanism of action; targeting the 
proton pump of ATP synthase 
(14)
. Although bedaquiline represents the first new drug 
approved to treat tuberculosis in 40 years, there are serious side effects accompanying 
treatment with this drug. Namely, bedaquiline has been reported to cause QT interval 




The antibiotic shortage is a problem because antibiotic resistance represents a 
serious global public health threat. With the incidence of multidrug resistant bacteria on 
the rise, the need for more effective anti-infective agents is urgent. Although antibiotics 
exist for the treatment of tuberculosis and malaria, these infectious diseases continue to 
account for over 3 million deaths annually 
(11)
. Although antibiotics exist for M. 
tuberculosis, extensively drug-resistant tuberculosis (XDR-TB) is resistant to even the 
most effective anti-TB drugs and therefore remains very difficult to treat 
(10)




to increasing the severity of disease, resistance is also driving up the cost of health care; 
about $20 billion a year in the United Stated alone 
(15)
. A resistant infection leads to 
longer hospital stays and treatment with second or third choice medications, which are 
less effective, more toxic, and more expensive. More efforts are required toward the 
development of effective anti-infective agents that require shorter treatment durations, 
smaller doses, and are more cost effective. In order to achieve these goals, new targets for 
anti-infective medications need to be examined. 
 
1.2 Isoprenoids are essential in Nature. 
Isoprenoids are the largest natural product class, comprising over 40,000 
compounds 
(16)
. These natural products are essential in all living organisms and are 
generated from two 5-carbon building blocks 
(17, 18)
: isopentenyl diphosphate (IDP) and 







Figure 1-2. Isoprenoid as building blocks for selected metabolites in bacteria and 
human pathogens. 
Isoprene units are assembled and modified in thousands of ways, leading to a high 
degree of structural diversity within the isoprenoid class. Compounds within this class are 
classified by the number of isoprene units (C5H8) they contain: monoterpenes, C10H16; 
sesquiterpenes, C15H24; diterpenes, C20H32; triterpenes, C30H48; tetraterpenes, C40H64; and 
polyterpenes, (C5H8)n 
(19)
. They are the building blocks that make up cholesterol, steroid 
hormones, ubiquinone, and fat soluble vitamins, in addition to many secondary 
metabolites found in all life forms 
(16)
 (Figure 2). Specifically in bacteria, the MEP 
pathway generates precursors to Lipid I and II, both of which are essential in bacterial 
cell wall biosynthesis 
(20, 21)
. Additionally, it was recently proposed that geranylation of 






Further, in both bacteria and the malaria parasites, isoprenoids are essential for processes 




1.3 Isoprenoid precursor biosynthesis. 
Although the isoprenoid natural product class is highly diverse structurally, all 
compounds within this class originate from IDP and DMADP 
(17, 18)
.  IDP and DMADP 
can be generated via the classical mevalonate (MVA) pathway. In this pathway, 
discovered in 1950 through isotopic labeling in feeding experiments 
(24, 25)
, three acetyl 
coenzyme A (acetyl-CoA) molecules undergo a series of condensation and reduction 
reactions to generate mevalonate (Figure 1-3). After mevalonate is phosphorylated to 
give mevalonate 5-diphosphate, mevalonate 5-diphosphate decarboxylase generates IDP, 
which can undergo isomerization to form DMADP. There are a number of drugs that 
target the mevalonate pathway in humans; specifically, statins are used to decrease 
cholesterol levels and the nitrogen-containing bisphosphonate class is used to treat 
various bone degenerative disorders 
(26)
. For decades, it was believed that the mevalonate 
pathway was the sole source of IDP and DMADP. However, work in bacteria in the 





C] acetate (a precursor to acetyl CoA) into the side 
chain of a bacterial hopanoid were inconsistent with IDP or DMADP derived from the 
MVA pathway 
(27)
. These experiments were then repeated in Escherichia coli and again 
the isoprenic units of the ubiquinone prenyl chain presented the same labeling pattern, 
independent of the MVA pathway. Feeding studies of [
13
C6] glucose were then performed 






.  These early studies demonstrated that pyruvate, not acetyl-CoA from 
the mevalonate pathway, is the precursor of a C2 subunit in the aforementioned 
organisms.  It also suggested a triose phosphate derivative as a precursor of a C3 subunit 
in the aforementioned organisms. Around the same time, an alternative isoprenoid 






Figure 1-3. Two independent routes to isoprenoid synthesis. The mevalonate pathway 
is present in plants, mammals and fungi. The methylerythritol phosphate (MEP) pathway 
is present in plants, bacteria, and apicomplexan parasites. 
 
In 1996, identification of the C3 subunit was reported using single mutants of E. 




to catalyze conversions between pyruvate and glycerol 
(30)
. Using labeled and unlabeled 
pyruvate and glycerol, they examined the labeling patterns in the prenyl chain of 
ubiquinone. All mutants incorporated the label from pyruvate into the C2 subunit, while 
labeling from glycerol was only found in mutants that lacked enolase, phosphoglycerate 
isomerase, and glyceraldehyde 3- phosphate (GAP) dehydrogenase. The results 
confirmed the key role of GAP as a precursor to the C3 subunit. The role of 1-deoxy-D-
xylulose (DX) in isoprenoid biosynthesis was first recognized in E. coli by Zhou et al in 




It was not until 1997 that the DXP synthase gene (dxs) was identified due to its 
homology with transketolase (TK), another thiamin diphosphate (ThDP)-dependent 
enzyme 
(32-34)
. Later, it was determined that DXP synthase is the first step in the non-
mevalonate, methylerythritol phosphate (MEP) pathway (Figure 1-3). It is now known 
that the MEP pathway generates IDP and DMADP in plants, most bacteria, and 
apicomplexan protozoa, such as the malaria parasite. The full pathway consists of seven 
enzymes to produce IDP and DMADP (Figure 1-3) and currently each enzyme in this 
pathway is under investigation as a potential anti-infective drug target. The MEP pathway 
for isoprenoid biosynthesis is not present in humans, but is essential in bacteria and 
human pathogens, such as Mycobacterium tuberculosis 
(35, 36)
 and the malaria parasites, 
including Plasmodium falciparum 
(37)
. Further, it has been shown that this pathway is 
required for virulence during mycobacterial infection of mice 
(38)
. Therefore, each 
enzyme in the pathway represents a novel target for the development of anti-infectives 




1.4 The methylerythritol phosphate (MEP) pathway as a drug target. 
Isoprenoids are diverse in cellular function (see section 1.2), so drugs that target 
the MEP pathway could act through a number of different cellular mechanisms. For this 
reason, anti-infective agents that target the MEP pathway have the potential to be 
developed as broad spectrum antibiotics. Validation for targeting this pathway comes in 
part from studies of fosmidomycin (3-(N-formyl-N-hydroxyamino)propyl-phosphonate), 
a specific, potent inhibitor of the second enzyme in the pathway, DXP 
reductoisomerase/MEP synthase (IspC). IspC catalyzes the NADPH and Mg
2+
 dependent 
transformation of DXP into MEP (for more information, see 1.13) 
(39)
 and fosmidomycin 
competes for the DXP binding site 
(40)
. Fosmidomycin was originally isolated from 
Streptomyces lavendulae culture broths during a 1980 study on organisms that produce 
phosphonic acid antibiotics 
(41)
. In 1999, fosmidomycin was shown to display inhibitory 
activity against purified Plasmodium falciparum IspC and suppress growth of 
Plasmodium in culture 
(42)
. Currently, it is in phase 3 clinical trials for the treatment of 
uncomplicated malaria in combination with clindamycin 
(43)
. However, fosmidomycin 
exhibits poor bioavailability due to its charged phosphonate group, absorption has been 
found to be only around 20-40% 
(44)
. Although it is a promising lead, more efficient 
antibiotics that target the MEP pathway are required. Studies presented in Chapter 5 
focus on addressing the poor pharmacokinetic properties of fosmidomycin and its 
analogs. 
There are several known inhibitors of the MEP pathway, although none have 
progressed as far in the drug development process as fosmidomycin. 5-Ketoclomazone, a 




influenzae and E. coli 
(45)





 show inhibitory activity against DXP synthase, but these 
compounds inhibit the enzyme in a non-specific manner. 2-C-Methyl-D-erythritol 2,4-
cyclodiphosphate tranferase (IspD) is modestly inhibited by L-erythritol 4-phosphate 
(48)
, 
but more potent inhibitors are needed against this enzyme that are more drug-like. The 
fourth enzyme in the pathway 4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol kinase 
(IspE), is inhibited by cytidine derivatives and tetrahydrothiophenyl derivatives, but these 
inhibitors display weak affinity and are non-selective 
(49)
. 2-C-Methyl-D-erythritol 2,4-
cyclodiphosphate synthase (IspF), the fifth enzyme in the pathway, was co-crystallized 
with fluorescent ligands that proved to be inhibitors of this enzyme 
(50)
. Additionally, 
thiazolopyrimidine inhibitors have also been identified, and are the most potent inhibitors 
of IspF described to date 
(50)
. HMB-PP synthase (IspG) and HMB-PP reductase (IspH) 
are inhibited weakly by alkyne-containing compounds that interact with the iron sulfur 
cluster in these enzymes 
(51, 52)
. Pyridyl inhibitors of IspH also show weak inhibitory 
effects against this enzyme 
(53)
. With the exception of fosmidomycin and its derivatives, 
inhibitors designed to target the MEP pathway enzymes are generally weak and non-
specific. Although the pathway was discovered over a decade ago and significant 
progress has been made toward understanding enzyme mechanism throughout the 
pathway, potent MEP pathway inhibitors that have the potential to become anti-infective 







1.5 Regulatory mechanisms of the MEP pathway. 
Despite the progress that has been made to understand the mechanisms of these 
enzymes, little is known about regulation of expression of the MEP pathway genes or 
control of flux through the pathway. In most bacteria, the MEP pathway genes are found 
throughout the genome, with no common motif between them, and no transcriptional 
regulators have been identified. However, studies carried out in Mycobacterium 
tuberculosis have taken the steps toward understanding pathway regulation in bacteria. 
Brown et al reported that increase in flux through the pathway was observed as a 
consequence of overexpression of IspG and DXP synthase (Dxs) 
(36)
. It was also observed 
that overexpression of DXP synthase resulted in increased HMB-DP production as well, 
mediated by increased transcription of the operon for IspC (dxr), which also contains 
ispG. These studies suggest that transcriptional control is affected by the first enzyme of 
the pathway, Dxs1, via an unknown regulator. Additionally, work in the Freel Meyers lab 
has tested the hypothesis that bacterial isoprenoid biosynthesis is controlled via feedback 
regulation of cyclodiphosphate synthase (IspF) 
(54)
. IspF, the fifth enzyme in the pathway, 
appears to bind to downstream isoprenoid metabolites (IDP/DMADP, GDP, or FDP) in a 
hydrophobic cavity as suggested by structural studies 
(55-58)
.  This suggested that feedback 
regulation of the MEP pathway might be occurring at the point of IspF. However, work 
from our lab has demonstrated that MEP is capable of activating and sustaining IspF 
activity, and only this complex is inhibited by FDP 
(54)
.  
 In plants, expression analysis of the MEP pathway genes under different 
conditions has shown coordinated regulation between genes in the pathway, suggesting 
common regulatory factors 
(59, 60)




levels of the pathway genes at any step result in a decrease in accumulation of the 
corresponding proteins, with the exception of Dxs and IspH, who did not show a decrease 
in protein levels 
(59, 60)
. Additionally, the authors reported that there is a buildup of Dxs 
protein levels in plants treated with fosmidomycin, and it was proposed that this is in 
response to changing demand for IDP and DMADP. They postulated that Dxs 
accumulation observed in these plant studies suggests a post-translational regulatory 
mechanism of the first enzyme in the pathway and warrants investigation in a bacterial or 
pathogenic model. Additionally, Sharkey et al has demonstrated that DXP synthase from 
Populus trichocarpa is inhibited by IDP and DMADP and both of these metabolites are 




1.6 DXP is a metabolic branch point. 
1-deoxy-D-xylulose 5-phosphate (DXP) synthase is the first enzyme in the MEP 
pathway and represents a metabolic branch point in bacteria and pathogens 
(29, 32, 62)
.  
DXP is not only a precursor to isoprenoids, but also functions as a precursor in thiamin 
diphosphate (ThDP, vitamin B1) in bacteria and Plasmodium, and pyridoxal phosphate 
(PLP, vitamin B6) biosynthesis in E. coli and a few members of the γ subdivision of 
proteobacteria 
(63-65)
 (Figure 1-4). The enzyme is unique in that it catalyzes formation of 






Figure 1-4. DXP synthase catalyzes the first step in IDP/DMADP biosynthesis and 




In the thiamin biosynthesis pathway in these organisms (Figure 1-5), the sulfur 
carrier protein ThiS undergoes adenylylation by ThiF, then a sulfur transfer step to yield 
the ThiS thicarboxylate (ThiS-COSH). After glycine (E. coli) or tyrosine (B. subtilis) is 
converted to dehydroglycine, thiazole synthase (ThiG) can then couple together DXP, 
dehydroglycine, and ThiS thicarboxylate to give the thiazole tautomer, which then 
aromatizes to form the thiazole phosphate carboxylate tautomer 
(65, 67)
. The pyrimidine 
ring of thiamin is formed by a rearrangement of 5-aminoimidazole ribotide (AIR) 
(68)
  to 
generate HMP-P, and then ThiD then phosphorylates HMP-P to give HMP-PP. After a 











This metabolic process is regulated by the ThDP riboswitch, one of the most 
widespread riboswitches found in Nature 
(65)
. When the intracellular concentration of 
ThDP is high, the aptamer domain of the riboswitch adopts a stable metabolite-bound 
conformation. When ThDP concentration is low, the ThDP dissociates from the 
riboswitch, leading to the expression of ThDP synthetic genes. Although bacteria and 
pathogens biosynthesize thiamin, a well-defined salvage pathway does exist in most 
microorganisms. Exogenous thiamin can be imported via an ATP-binding cassette 
(ABC), and then converted to thiamin-diphosphate. However, pathogens like 
Mycobacterium tuberculosis lack this salvage pathway 
(64)
, so inhibitors designed to 
block thiamin biosynthesis in organisms such as these should result in decreased survival 




There are two distinct pathways for the biosynthesis of PLP 
(63)
. The DXP-
independent (ribose 5-phosphate dependent) route is widely distributed in four kingdoms 
of life 
(69-72)
 and has been extensively studied 
(73-79)
. It uses PLP synthase, an enzyme 
composed of two subunits that function together as the glutamine amidotransferase. In 
the presence of ammonia, GAP, and ribose 5-phosphate, PLP is generated in a set of 
complex reactions. The DXP-dependent pathway for PLP biosynthesis (Figure 1-6) is 
found in E. coli and a few members of the gamma subdivision of proteobacteria, 
including Salmonella, Yersinia, V. cholerae, and K. pnemoniae 
(80)
. It requires the 
convergence of DXP and 1-amino-propan-2-one-3-phosphate, produced from erythrose 
4-phosphate, to generate pyridoxine 5-phosphate. Using primarily the E. coli model 
system, the PLP salvage pathway has been well characterized 
(32, 81-90)
 and it is generally 
agreed upon that the various forms of vitamin B6 are interconvertible. However, the 
vitamin B6 transporter has not yet been identified. 
Both ThDP and PLP are essential cofactors in all living organisms. Humans 
depend solely on dietary uptake of thiamin and pyridoxal phosphate, so it is logical that 
these metabolic networks in bacteria and pathogens are suitable drug targets for anti-
infectives. As DXP synthase biosynthesizes a precursor for both of these networks, in 







Figure 1-6. The DXP-dependent biosynthetic pathway for pyridoxal phosphate 
(PLP). 
 
1.7 Alternative pathways for DXP/MEP production. 
Although inhibition of the MEP pathway ought to simultaneously reduce flux 
through multiple essential pathways, the emergence of mechanisms to circumvent such 
an intervention in bacteria is inevitable. In a recent study by Perez-Gil et al 
(91)
, the lethal 
phenotype that was observed in E. coli by deleting dxs or ispC was partially suppressed 
by mutations in the unrelated genes aceE and ribB. The aceE gene encodes for pyruvate 
dehydrogenase (PDH), and the E636Q 
(92)




rescue the deficiency of dxs. PDH is thiamin-dependent enzyme that has been previously 
shown to catalyze the formation of DX from pyruvate and D-glyceraldehyde, albeit very 
inefficiently 
(93, 94)
. It has also been shown that DX can be phosphorylated to DXP by D-
xylulose kinase 
(95)
. Presumably, these mutations within the active site of PDH alter 
enzyme activity to permit more efficient turnover to generate DX.  
The ribB gene encodes 3,4-dihydroxy-2-butanone-4-phosphate synthase 
(DHBPS), whose catalysis involves a series of steps including dehydration, 
intramolecular rearrangement and rehydration of D-ribulose 5-phosphate to formate and 
3,4-dihydroxy-2-butanone 4-phosphate
(96)
. The authors speculate that the G108S and 
D113G mutant enzymes are capable of generating DXP by utilizing either D-ribulose 5-
phosphate or its isomer D-xylulose 5-phosphate as substrates. 
In another study by Erb et al, an alternative pathway to DXP was identified in the 
photosynthetic, facultative anaerobe Rhodospirillum rubrum 
(97)
. In this study, the authors 
linked polyamine metabolism to the MEP pathway by identifying a series of enzymes 
that catalyze DXP generation from the 5-methylthioadenosine (MTA) byproduct. Under 
most circumstances, MTA is cleaved and phosphorylated to generate 5-methylthio-D-
ribulose 1-phosphate (MTRP), and subsequently methionine 
(98)
. However, in R. rubrum, 
an atypical RLP (rubisco-like protein) isomerizes MTRP to 1-methylthio-D-xylulose 5-
phosphate (MTXP), and then MTXP methylsulfurylase (MMS) converts MTXP into 
DXP.  Genomic analysis revealed that enzymes involved in this metabolic shunt are 
conserved in several groups of bacteria, including Rhodopseudomonas palustris, 
Methylocella silvestris, Rhodomicrobium vannielii, Meiothermus silvanus, and 




relevancy of this shunt remains questionable as a potential mechanism of resistance to 
anti-infectives targeting the MEP pathway. 
 
1.8 Thiamin-diphosphate (ThDP)-dependent enzymology. 
The ThDP cofactor is present in all living systems (see 1.6 for more information 
regarding thiamin biosynthesis). This essential nutrient was first discovered in the 1930s 
by Robert Williams through its link to the nervous system disease, Beriberi 
(99)
. ThDP 
consists of an aminopyridine ring connected via a carbon linker to a thiazole ring, which 
contains a diphosphate group (Figure 1-7A). Reactive intermediates along the reaction 
coordinate are linked to the cofactor at the C2 position of thiazole ring. 
 
 
Figure 1-7. The thiamin diphosphate cofactor. A) ThDP shown with the pyrimidine 
ring in blue, thiazole ring in red, and C2 hydrogen in green. B) Enzymology for pyruvate-
utilizing ThDP-enzymes. The pyruvate donor substrate is highlighted in red, with the 






Although ThDP-dependent enzymes can differ mechanistically (Figure 1-8), 
common themes are evident in the chemical mechanism of pyruvate-utilizing enzymes 
(100-102)
 (Figure 1-7B). Deprotonation at the C2 position generates the corresponding ylide 
intermediate, and the resulting carbanion/enamine is able to act as a nucleophile in this 
chemical mechanism. The carbanion attacks the carbonyl group on the donor substrate 
(pyruvate) to generate the lactyl-ThDP (LThDP) tetrahedral intermediate. The positively 
charged nitrogen on the thiazole ring then acts as an electron sink and drives release of 
the first product to generate the C2-α carbanion/enamine intermediate. This is a central 
intermediate in ThDP-dependent enzymology.  
ThDP is an important cofactor in several biochemical reactions (Figure 1-8), such 
as: 1) oxidative and nonoxidative decarboxylation of alpha-keto acids (E1 subunit of 
pyruvate dehydrogenase, pyruvate decarboxylase, benzoylformate decarboxylase) 2) the 
formation of amino acid precursors (acetolactate synthase) 3) electron transfer reactions 
(pyruvate oxidase, pyruvate:ferredoxin oxidoreductase/pyruvate synthase) and 4) ketol 
transfer between sugars  (transketolase). The common thread throughout all of these 
reactions is that the acceptor substrate, the second substrate, cannot enter the active site 











Figure 1-8. ThDP-dependent biochemical reactions. Abbreviations used: Pyruvate 
oxidase (POX), flavin adenine dinucleotide (FAD), E1 subunit of pyruvate 
dehydrogenase (E1 PDH), coenzyme A (CoA), pyruvate decarboxylase (PDC), 





Many studies have focused on ThDP cofactor activation toward understanding 
factors that drive the initial deprotonation step at the C2 position. Structural evidence 
shows the presence of a conserved glutamate residue that is in hydrogen bonding distance 
from the N1’ position of the aminopyrimidine ring 
(104-107)
. Site-directed mutagenesis and 
spectroscopic studies 
(108-110)
 show the 4’-aminopyrimidine ring and the highly conserved 
interaction between a glutamate and the N1’ of the cofactor are integral components of a 
proton relay that promotes ionization at the C2 position and activation of the cofactor 
(Figure 1-9).  
Circular dichrosim (CD) studies have identified the tautomeric forms and 
ionization states of the cofactor for several ThDP-dependent enzymes 
(111)
 (Figure 1-9). 
The signature for the 4-aminopyrimidine (AP) form of ThDP is a negative band near 320-
330 nm.  This CD band is due to a charge transfer transition between the AP ring as a 
donor and the thiazolium ring as an acceptor. The 1,4-iminopyrimidine (IP) form gives 
rise to a positive CD band in the 300-314 nm range. There is no electronic absorption 
characteristic for the APH+ form; however the pKa for the APH+ coincides with the pH 
optimum for each enzyme, indicating that all three forms (AP, IP, APH+) must be 
available during the catalytic cycle. These studies provide evidence for the participation 






Figure 1-9. ThDP tetrahedral intermediates. A) Tautomerization states B) CD spectra 
of human E1 PDH titrated with ThDP. The spectra revealed the presence of both the IP 






H-NMR fingerprint approach has also been used to study key intermediates 
in ThDP-dependent enzymes during catalysis 
(112)
. This method directly detects 
intermediates on the basis of differences in the corresonding 
1
H-NMR spectra and 
determines the quantitative distribution in an enzymatic reaction. This approach has been 




Finally, decarboxylation among ThDP-dependent enzymes has been extensively 
studied using nonenzymatic LThDP models. For example, Kluger et al has measured a 











 fold increase in the rate of decarboxylation has been reported when the 2-(1-
carboxy-1-hydroxyethyl)-3,4-dimethyl-thiazolium ion is transferred from water to 
ethanol 
(114)
. “Spontaneous” decarboxylation has also been reported for C2α-




. Collectively, these studies 
argue that CO2 is a powerful electrophile, and decarboxylation may be reversible prior to 
separation of the CO2 molecule from the residual carbanion. In summary, while there are 
subtleties in the mechanisms of the ThDP-dependent class of enzymes that remain 
unknown, they are generally well-studied with a number of methods available to research 
these enzymes, and common mechanistic themes prevail within this enzyme class. 
 
1.9 Inhibitors of thiamin diphosphate (ThDP)-dependent enzymes. 
Although the ThDP-dependent enzymes are well studied, there are few reports of 
inhibitors that selectively target these enzymes. For example, bacimethrin (Figure 1-10) 
is an analog of hydroxymethylthiamin-PP (HMP), an intermediate in the thiamin 
biosynthetic pathway 
(116)
. Bacimethrin inhibits ThDP-dependent enzymes non-
specifically and requires intracellular activation by enzymes in the thiamin biosynthetic 
pathway. The low micromolar inhibitiory activity observed by bacimethrin against E. coli 
can be abrogated by supplementing the growth media with low levels of thiamin or HMP. 
As discussed in section 1.4, inhibitors that have been evaluated against DXP synthase (5-




inhibit ThDP-dependent enzymes in a non-specific manner. Methylacetylphosphonate 
(MAP) (Figure 1-10) is a pyruvate analog that has been extensively used to study the 
mechanism of ThDP-dependent enzymes, and while it is a relatively potent inhibitor 
against this enzyme class (average Ki for ThDP enzymes ~ 1 µM), it also inhibits non-
specifically 
(117-124)
. The mechanisms of inhibition of fluoropyruvate and MAP will be 
discussed in more detail in Chapter 2.  
 
 
Figure 1-10. Inhibitors of ThDP-dependent enzymes. 
 
Dehydrophos is a phosphonotripeptide natural product from Streptomyces luridus 
that exhibits broad spectrum activity as an antibiotic in vitro and also in vivo against 
Salmonella typhimurium challenged chickens 
(125)
. It is imported via oligopeptide 
permeases and subsequently cleaved by intracellular peptidases to release MAP 
(126)
. The 
peptide moiety of dehydrophos acts as a “Trojan horse” that allows it to be readily taken 
up by the cell and released after the cleavage event, where it then is believed to inhibit 
ThDP-dependent enzymes, such as PDH and DXP synthase. Although the charged 




found a way to circumvent this by masking this charge in the dehydrophos natural 
product. 
 
1.10 DXP synthase enzymology. 
1.10.1 DXP synthase enzyme characterization. 
DXP synthase combines elements of decarboxylase and carboligase ThDP-
dependent chemistry by catalyzing the decarboxylation of pyruvate and subsequent 
condensation of this two carbon donor substrate with D-glyceraldehyde 3-phosphate (D-
GAP) (Figure 1-3) 
(32)
. DXP synthase enzymes have been identified, cloned, purified, 
and characterized from a number of bacterial species 
(42, 45, 47, 127-130)
 (Table 1-2). DXP 
synthase is also the subject of numerous botanical reports. Differences in the kinetic 
parameters reported for each of these enzymes appear to be affected by the buffer chosen 
for each study (for more information on buffer effects, see section 2.2.1). Despite the 
many reports of DXP synthase enzymes from plants and Mycobacterium tuberculosis, 
Haemophilus influenzae, and E. coli, there is a notable gap in the literature for 
purification of pathogenic DXP synthase enzymes. Characterization of Mycobacterium 











species Km D-GAP (µM) Km pyruvate (µM) kcat (min
-1
) reference 
Escherichia coli 226 1000 246 
(126)
  
Rhodobacter capsulatus 68 440 114  
(47)
 
Streptomyces  coelicolor 
300 600 66 
(128)
 
570 200 66 
Mycobacterium tuberculosis 6 40 N/A  
(129)
  
Haemophilus influenzae 190 190 N/A 
(45)
  
Populus trichocarpa 19 89 30 
(61)
   
 
Table 1-2. DXP synthase steady-state kinetics. Reported kinetic constants for bacterial 
characterization of DXP synthase enzymes. *P. trichocarpa was selected as an example 
for characterization of the plant enzyme. 
 
M. tuberculosis DXP synthase was first identified in 2002 and partially 
characterized by Bailey, et al 
(129)
. In this initial study, the Rv2682c (dxs1) and Rv3379c 
(dxs2) genes were identified as encoding proteins that are similar in primary structure to 
E. coli DXP synthase (~38%). Only two other bacterial species have been discovered that 
contain two homologs of DXP synthase: Rhodobacter capsulatus 
(131)
 and Streptomyces 
coelicolor 
(128)
. However, in these species both dxs genes encode functional enzyme. On 
the basis of an N-terminus truncation, it was hypothesized that dxs2 from M. tuberculosis 
encodes a non-functional enzyme. This was postulated on the basis of the observation 
that the N-terminal deletion results in the absence of a residue that corresponds to H49 in 
E. coli DXP synthase. Although it was previously proposed that H49 is critical to 
catalysis 
(132)
, work from our lab shows that H49 is not absolutely essential 
(133)
. This 
warrants further studies on the catalytic activity of Dxs2.  For M. tuberculosis Dxs1, there 
are still several questions remaining. Bailey et al reported Dxs1 substrate affinity (Km) 




efficiency (kcat / Km) were not reported in this study 
(129)
. Interestingly the enzyme is 
capable of turning over both D-glyceraldehyde and L-glyceraldehyde, which is unusual as 
most transketolases are specific for the D configuration 
(134)
. They also found the enzyme 
was capable of turning over D-erythrose 5-phosphate, but not D-ribose 5-phosphate. In 
order to design inhibitors of the enzyme that would exhibit potential as broad spectrum 
antibiotics, the mechanism of Dxs1 and DXP synthase from additional pathogenic species 
should be further investigated. 
 
1.10.2 DXP synthase kinetic mechanism. 
As a ThDP-dependent enzyme, DXP synthase is underdeveloped as a drug target. 
This is presumably due to concerns about achieving selective inhibition over mammalian 
ThDP-dependent enzymes, such as the E1 subunit PDH and TK. Indeed, E. coli DXP 
synthase active site residues are conserved relative to other ThDP-dependent enzymes. 
These include His-49, proposed to play a role in proton transfer in a manner similar to 
that of His-30 in transketolase, and Glu-370, thought to be essential for cofactor 
activation 
(132)
. Yet DXP synthase is a unique enzyme among the ThDP-dependent class, 
as it exhibits a novel domain architecture and kinetic mechanism 
(135)
. The Deinococcus 
radiodurans DXP synthase crystal structure 
(135)
 shows that the enzyme has a distinctive 
domain arrangement. The active site is located between domains I and II of the same 
monomer, versus other ThDP-dependent enzymes whose active sites reside at the dimer 
interface.  
Additionally, early work by Eubanks and Poulter on the kinetic mechanism of 




from other ThDP-dependent enzymes 
(47)
 despite the similar carboligation transformation 
it catalyzes. All other ThDP-dependent enzymes are believed to operate via a classical 
ping-pong mechanism, whereas CO2 trapping studies have provided compelling evidence 
for the requirement of a ternary complex in DXP synthase catalysis. Interestingly, slow 
CO2 release was observed in the absence of D-GAP, which can be explained by the 
acetolactate synthase activity as a side reaction of DXP synthase reported by our group in 
a subsequent study of DXP synthase substrate specificity 
(127)
. Based on these 
experiments, as well as steady-state kinetic studies, Eubanks and Poulter proposed an 
ordered substrate binding model, in which pyruvate binds essentially irreversibly to the 
free enzyme prior to binding of D-GAP (Figure 1-11A).  
 
 
Figure 1-11. Proposed mechanistic models for DXP synthase. E, ThDP-bound 
enzyme; Pyr, pyruvate; Pyr*, enamine/carbanion; G, D-GAP; E-Pyr-G, catalytically 
competent ternary complex. A) ordered mechanism where pyruvate binds tightly and 
essentially irreversibly to DXP synthase
(47, 136)
. B) ping-pong mechanism where CO2 







A more recent study reported a single-molecule force spectroscopy nanosensor to 
measure E. coli DXP synthase substrate binding and application of single-molecule force 
spectroscopy for identifying beta-fluoropyruvate as an inhibitor of the enzyme 
(136)
. Using 
immobilized enzyme and substrate, the authors determined substrate binding constants 
and suggested that the observed 1.7-fold enhancement in binding of D-GAP to DXP 
synthase in the presence of soluble pyruvate provides further support for an ordered 
mechanism. A conflicting report 
(45)
 proposes, on the basis of steady-state kinetics, that E. 
coli and Haemophilus influenzae DXP synthase operate via a classical ping-pong 
mechanism in a manner similar to other ThDP-dependent enzymes (Figure 1-11B). 
 
1.11 Challenges in antimicrobial development.  
 With antibiotic resistance on the rise, there has been a recent push to develop new 
classes of drugs to combat resistant bacteria and pathogens. Nevertheless, there are 
specific challenges in targeting these organisms that present difficulties in the drug 
discovery process. For example, in addition to the cellular membrane, prokaryotes have a 
cell wall composed of peptidoglycan, a waxy polymer consisting of sugars and amino 
acid building blocks 
(137)
. The peptidoglycan layer makes up 90% of the dry weight of the 
Gram positive cell. The peptidoglycan layer for Gram negative bacteria is much smaller; 
the dry weight is only around 10% 
(138)
. Yet cellular transport is especially difficult 
because Gram negative bacteria typically have a thick outer lipid membrane. This 
mechanical permeability barrier prevents the entry of small molecules larger than 2 nm 
(139)
. In bacteria, cellular entry of an antibiotic is also restrained by the amphipathic nature 




membrane, the antibiotic can still be ejected by an efflux pump. Entry is especially 
difficult in Gram negative bacteria, whose barrier contains multi-drug resistant (MDR) 
pumps that are specific for amphipathic molecules 
(2, 3)
. This poor cellular uptake requires 
higher doses of antibiotics for effective treatments. Although the affinity of an antibiotic 
to its purified target is typically comparable to a typical drug for a eukaryotic target, the 
effective dose is two to three orders of magnitude higher 
(140)
. This can result in higher 
toxicity, presenting challenges in the drug development and approval process for new 
classes of antibiotics. 
 
1.12 Antimicrobial combination therapy and synergy. 
 Antibiotic combinations are used for patients who are either seriously ill and may 
be septicemic, or to prevent the spread of resistance. For example, combinations of 
isoniazid and rifampicin have been used for the treatment of tuberculosis for over fifty 
years 
(10)
. Combinations such as these suppress the emergence of resistance by 
probability; the chance of bacteria harboring multiple spontaneous, independent resistant 
mutations to several antibiotics is unlikely. Another benefit is that antibiotics 
administered in combination usually require a lower dosage, and this reduces dose-related 
toxicity of these drugs 
(141)
. In most cases, the lower dosage of antibiotics when used in 
combination was believed to be the result of antibiotic synergy. Although there are 
several definitions of the term synergy, it generally means that the effect of a drug in 
combination is greater than the sum of their effects alone 
(142, 143)
.  
There are several laboratory methods to evaluate the activity of antimicrobial 
combinations 
(142-144)




checkerboard refers to the pattern produced by multiple drug dilutions of the two 
antimicrobials being tested (Figure 1-12).  Each antimicrobial is serially diluted at 
concentrations above and below its minimum inhibitory concentration (MIC). The MIC is 
the amount of antimicrobial required to inhibit overnight growth of the bacterial strain 
evaluated.  From the checkerboard, one obtains a fractional inhibitory concentration 
(FIC) index, a predictor of synergy between the two antibiotics tested. Synergy involves a 
four-fold or greater decrease in the minimum inhibitory concentration of each antibiotic 
when used in combination, which corresponds to an FIC index of < 0.5 (for more 
information, see Chapter 4). After each organism is scored for growth, an isobologram 
can be generated (Figure 1-12).  If the dose pair relationship is below the line of 










Figure 1-12. Evaluating antibiotic combinations. A) The checkerboard assay is used to 
determine the fraction inhibitory concentration (FIC) index between two antibiotics 
tested. An FIC < 0.5 is considered synergistic. B) An isobologram is another way to 
represent the checkerboard data. If the dose pair relationship is below the line of 
additivity, the relationship is considered synergistic. SYN = synergistic, ADD = additive, 
ANT = antagonistic 
(142-144)
.   
 
In addition to the clinical implications of drug synergy, synergistic relationships 
have also been used to study drug mechanism of action. Synergy can occur for a number 
of reasons, as combinations could have: 1) different targets of the same pathway that 
regulate the same process, 2) different targets of the same pathway that regulate the same 
target, 3) different targets of related pathways, or 4) the same target itself. When synergy 






Drug combination studies continue to be a useful tool for researching not only antibiotics, 
but also for drugs with eukaryotic targets as well. 
 
1.13 Inhibition of DXP reductoisomerase by fosmidomycin and its analogs. 
DXP reductoisomerase (IspC) is the first committed step of the MEP pathway. 
IspC catalyzes the reduction and rearrangement of DXP to generate MEP, and this occurs 
in an NAPDH and magnesium dependent manner (Figure 1-13) 
(39)
. As discussed in 
section 1.4, fosmidomycin is a potent inhibitor of IspC (Km
DXP
 = 115 µM; Ki
fosmidomycin
 = 
57 nM for Synechocystis sp. PCC6803 IspC 
(146)
); it binds tightly in the active site of IspC 
in a time-dependent manner 
(147)
. The E. coli IspC crystal structure shows that 
fosmidomycin binds in a similar manner as DXP; the flexible loop that is open in the apo 
form of IspC covers the active site when bound to fosmidomycin or DXP in a phosphate 
induced mechanism 
(148)
. There are three regions of the substrate binding cavity: a 
positively charged pocket, which binds the phosphonate moiety, a hydrophobic region 
around the carbon backbone, and an amphipathic region, which binds to the hydroxamic 
acid moiety. Structure activity relationship studies show that the phosphonyl and 
hydroxamic acid groups are essential binding elements, and isosteric replacement of the 
phosphonyl group abolishes inhibitory activity 
(149, 150)
 (Figure 1-13).  Replacement of 
the phosphonyl group with sulfonamide, carboxylate, and carboxamide result in a large 
decrease in inhibitory activity 
(146)
. The phosphoryl analog of fosmidomycin (fosfoxacin) 
and its N-acetyl congener (FR900098) have been shown to be more potent inhibitors of 













Although fosmidomycin has shown promise as an anti-malaria agent in 
combination with clindamycin 
(43)
, it displays poor bioavailability, and this presumably 
results from poor cellular permeability 
(44)
. Several strategies have been explored to 
increase the permeability of fosmidomycin. Alpha-substituted lipophilic analogs increase 
permeability, but decrease inhibitory activity against purified IspC 
(151)
. Other studies 
have centered on generating fosmidomycin/FR900098 prodrugs, employing 
biodegradable delivery groups that rely upon two bioactivation steps catalyzed by 
esterases or phosphatases 
(152, 153)
. Although these prodrugs resulted in improved 
bioavailability, esters such as these are unstable in serum, leading to premature, 
extracellular activation and formation of membrane impermeable intermediates 
(154)
. 




to improve the efficacy of fosmidomycin, more work is needed to overcome the 
difficulties presented by the charged moiety of this compound.  
Results of our studies support the unique requirement for ternary complex 
formation in DXP synthase catalysis and highlight the flexibility of this enzyme for 
aliphatic acceptor substrates. Taken together, these observations have guided the design 
of a new class of DXP synthase inhibitors, acetylphosphonates. The unnatural bisubstrate 
analog, butylacetylphosphonate (BAP), exhibits selective inhibition of DXP synthase 
over ThDP-dependent enzymes. Further, BAP displays antimicrobial activity and is 
shown to act in synergy with other antimicrobial agents. These results suggest a new 
approach for selective inhibition of early stage isoprenoid biosynthesis, toward 
development of new anti-infective agents. Additionally, work presented here proposes 
new strategies to overcome bioavailability issues of fosmidomycin and improve its 
efficacy as an antibiotic.  
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 1-deoxy-D-xylulose 5-phosphate (DXP) synthase is a ThDP-dependent enzyme 
that catalyzes the decarboxylation of a pyruvate and subsequent condensation of the two 
carbon donor substrate with the D-glyceraldehyde 3-phosphate acceptor substrate to 
generate DXP 
(1)
. Combining elements of carboligase and decarboxylase chemistry, it 
shares weak sequence homology (~20%) with transketolase and the E1 subunit of 
pyruvate dehydrogenase 
(2)
. The DXP synthase-catalyzed reaction is reminiscent of 
acetolactate synthase and glyoxylate carboligase, which generate acetohydroxyacid and 
tartronate semialdehyde, respectively, via similar decarboxylation and carboligation 
chemistry, as well as transketolase whose acceptor substrate is also an aldehyde. 
Although DXP synthase is essential in most bacteria and human pathogens 
(3-5)
, it is 
undeveloped as a drug target. This is most likely due to perceived challenges in targeting 
a ThDP-dependent enzyme; examples of selective inhibitors against this class are lacking. 
However, DXP synthase is unique among ThDP-dependent enzymes. In addition to a 
novel domain arrangement 
(2)
, there have also been reports that the kinetic mechanism is 
distinct 
(6, 7)
. Yet there are discrepancies in the literature regarding this mechanism that 







Figure 2-1. Reaction catalyzed by DXP synthase. 
 
Previous mechanistic studies on DXP synthase that have relied primarily upon 
kinetic analysis concluded that the enzyme follows a ping-pong mechanism 
(8)
, similar to 
all other ThDP-dependent enzymes. In this ping-pong mechanism, pyruvate is proposed 
to bind to the enzyme first, undergo decarboxylation, and then D-GAP enters the active 
site and the C-C forming reaction can proceed (Figure 2-2A). However, Eubanks et al 
used kinetic analysis and CO2 trapping studies to provide evidence for ternary complex 
formation in a proposed ordered mechanism, with pyruvate binding first, tightly and 
essentially irreversibly 
(6)
 (Figure 2-2B). ). These studies, as well as work presented in 
this chapter, presume that decarboxylation is an essentially irreversible event. However, 
CO2 release has been proposed to be reversible for other ThDP-dependent enzymes (see 
1.8). Similar studies have not yet been carried out for DXP synthase. The ternary 
complex represents a ThDP-bound enzyme conformation in which both substrates are 
bound to the active site prior to catalysis. During the course of this work, we have 





Figure 2-2. Proposed kinetic mechanisms for DXP synthase. E, ThDP-bound enzyme; 
Pyr, pyruvate; Pyr’, enamine; GAP, D-GAP; E-Pyr-G, catalytically competent ternary 
complex. A) Ordered mechanism where pyruvate binds tightly and essentially 
irreversibly to DXP synthase
(6)
. B) Ping-pong mechanism where CO2 liberation occurs 




Ultimately, our interest in pursuing the development of selective DXP synthase 
inhibitors requires knowledge of the kinetic mechanism and catalysis. Features that 
distinguish DXP synthase from other ThDP-dependent enzymes can be exploited in the 
development of new anti-infective agents that target this first essential step in pathogen 
isoprenoid biosynthesis. Ideally, inhibitors of E. coli DXP synthase will be effective 
against DXP synthase enzymes from different pathogens and therefore have the potential 




a number of organisms, including plants 
(11, 12)
 or non-pathogenic bacteria 
(6, 13, 14)
, 
primarily for the purpose of bioengineering. Although some work has been performed to 
understand the mechanism of DXP synthase from R. capsulatus 
(6)
 and Mycobacterium 
tuberculosis 
(15)
, mechanistic studies from additional pathogens are required to investigate 
the generality of mechanism. In addition to mechanistic studies on E. coli DXP synthase, 
this work concentrates on Yersinia pestis, Salmonella typhimurium, and Mycobacterium 
tuberculosis DXP synthase. Both S. typhimurium and Y. pestis DXP synthase have 
similar primary amino acid sequence identity with the E. coli enzyme (~90%) (Table 2-
1). Mycobacterium tuberculosis DXP synthase (Dxs1) is the least similar to each of the 
three (~40%).  
 
 
M. tuberculosis S. enterica E. coli 
Y. pestis 38% 83% 83% 
M. tuberculosis   40% 40% 
S. enterica     96% 
 
Table 2-1. DXP synthase primary amino acid sequence identity 
(16). 
 
Y. pestis is the causative agent of the plague, of which there are still thousands of 
cases a year reported to the World Health Organization (WHO). Due to the possibility of 
a bioterrorist aerosolized release, Y. pestis also represents a potential bioterrorism threat 
and is categorized as a category A pathogen (Center for Disease Control, CDC) 
(17)
. S. 
typhimurium is a Gram negative bacterium and its serotypes form a group of pathogens 
that can result in gastroenteritis, typhoid fever, among other diseases. S. typhimurium (S. 
enterica serovar Typhimurium) is of particular interest in anti-infective development due 
to the emergence of the definitive phage type (DT) 104 
(18)
. This phage type strain is 




chloramphenicol/florfenicol, spectinomycin/streptomycin, sulfonamides, and 
tetracyclines.  Several outbreaks have already occurred since 1996 in the United States 
and Canada, and S. enterica serovar Typhimurium DT 104 represents a global health 
problem.  Although antibiotics exist for M. tuberculosis, extensively drug-resistant 
tuberculosis (XDR-TB) is resistant to even the most effective anti-TB drugs and therefore 
remains very difficult to treat. Currently, one third of the world’s population infected 
with TB 
(19)
; thus, new more effective treatments are desperately needed. 
The focus of this chapter is the elucidation of the mechanism of E. coli DXP 
synthase using inhibition kinetics, model discrimination analysis (in collaboration with 
Leighanne Brammer Basta, PhD), and molecular docking to distinguish between ordered 
and ping-pong kinetic mechanisms. The generality of the kinetic mechanism is then 
explored amongst DXP synthase from more pathogenic species: M. tuberculosis, S. 
typhimurium, and Y. pestis. We take initial steps to evaluate subtleties in the cofactor 
binding site of M. tuberucloisis Dxs1 using site-directed mutagenesis. Collectively, our 
results suggest the enzyme proceeds via novel rapid equilibrium, random sequential 













2.1. Kinetics using natural substrates of E. coli DXP synthase. 
 2.1.1. Buffer optimization studies. 
Prior to beginning kinetic studies toward elucidating the mechanism of E. coli 
DXP synthase, buffer optimization studies were carried out to ensure optimal enzyme 
activity conditions. In our buffer optimization study, decreased turnover efficiency was 
observed when reactions were performed in Tris (2-amino-2-hydroxymethyl-propane-
1,3-diol) and citrate, buffers reported previously for mechanistic studies of DXP synthase 
(6, 8)
. In Tris buffer, Km
D-GAP 
values increased with increasing Tris concentration (Table 2-
2). This can be attributed to D,L-GAP instability in Tris, presumably a consequence of the 





























40 mM HEPES 30 ± 5 79 ± 5 230 ± 7 7.6 ± 0.9 3.0 ± 0.2 
100 mM HEPES 24 ± 2 49 ± 8 154 ± 7 6.9 ± 0.4 3.2 ± 0.5 
40 mM Tris 53 ± 8 86 ± 16 146 ± 13 3.1 ± 0.2 1.6 ± 0.2 
100 mM Tris 279 ± 7 75 ± 7 209 ± 6 0.8 ± 0.04 2.7 ± 0.2* 
100 mM TEA 36 ± 5 129 ± 13 173 ± 11 5.6 ± 0.6 1.2 ± 0.1 
100 mM 
phosphate 
226 ± 32 1100 ± 300 246 ± 13     
 
Table 2-2. Summary of kinetics parameters for wild type E. coli DXP synthase in 
different buffer systems 
(21)
. *Performed in duplicate. 
 
Citrate buffer was found to inhibit DXP synthase and IspC (Figure 2-3) which is 
consistent with its properties as a magnesium chelator 
(22)




describe kinetic experiments performed at higher varying substrate concentrations 
relative to concentration ranges of natural substrates in the present study. Presumably, 
these conditions were required to overcome the inhibitory effects and reactivity of these 
buffered systems.  
 




2.1.2. D-GAP and pyruvate exhibit substrate inhibition.  
Mechanistic insight was obtained through kinetic analysis of wild-type E. coli 
DXP synthase. DXP formation was monitored using the IspC-coupled reaction 
(23)
, and 
double-reciprocal plots of the natural substrates at varying concentrations were generated 
by plotting inverse initial velocities of DXP formation as a function of inverse substrate 
concentration at fixed concentrations of the second substrate in each case (Figure 2-4).  
In both a ping-pong and an ordered mechanism, in which pyruvate binds first, a 
competitive profile should be apparent with respect to both pyruvate and D-GAP 
(24-26)
. 
For a rapid equilibrium, random sequential mechanism in which either substrate is 
capable of binding in the active site the absence of the other, a noncompetitive profile 
should be evident with respect to both substrates. Likewise, an ordered mechanism in 
which pyruvate binds first, tightly and essentially irreversibly, also predicts a 
noncompetitive relationship for both substrates 
(6)




mechanism such as this is in disagreement with recent equilibrium binding studies that 
show pyruvate binds reversibly to the active site 
(27, 28)
 . Interestingly, the double-
reciprocal plots shown in Figure 2-4 exhibit apparently different trends at higher 
concentrations of the fixed second substrate. Under conditions where D-GAP is the varied 
substrate, the slopes exhibit a noncompetitive relationship at low concentration of 
pyruvate (12.3–36.8 µM) but appear to increase subtly with increasing fixed pyruvate 
concentrations (49.0–98.0 µM), suggesting substrate inhibition by pyruvate 
(24-26)
. The 
apparent increase in slopes is more pronounced when pyruvate is varied at fixed, sub-
saturating concentrations of D-GAP (48.0–73.0 µM), suggesting substrate inhibition by 
D-GAP also takes place.  
 
 
Figure 2-4. Double reciprocal analysis of initial velocities under conditions where 
either D-GAP or pyruvate is varied at different fixed concentrations of the co-
substrate 
(21)
. Kinetic analyses were performed by varying subsaturating concentrations 
of D-GAP: 18 (○), 24 (●), 36 (□), 48 (■), 60 (△), 72 (▲) µM at varying sub-saturating 





The kinetic data were re-evaluated by a global non-linear regression analysis 
using the computer simulation program DynaFit (Leighanne Brammer Basta, PhD) 
(29)
. 
Several mechanistic models for a two substrate, two product (Bi Bi) system were 
examined in a model discrimination analysis by the Akaike Information Criterion 
method, including rapid equilibrium ordered (where pyruvate binds first), rapid 
equilibrium ordered (where D-GAP binds first), ordered (where pyruvate binds first and 
irreversibly), rapid equilibrium random sequential, and rapid equilibrium ping pong. All 
models investigated presumed irreversible decarboxylation of LThDP. In this analysis, 
model discrimination supported a rapid equilibrium, random sequential mechanism of 
DXP synthase (Figure 2-5). However, inspection of this global fit reveals apparent 
deviation of the empirical data from predicted trends in a random sequential mechanism, 
suggestive of substrate inhibition and in agreement with the Lineweaver-Burk analyses. 
We have previously reported a side reaction of DXP synthase involving the formation of 
acetolactate from two molecules of pyruvate 
(30)
, which is consistent with the notion of 
substrate inhibition by pyruvate. Indeed, a random sequential model considering this side 
reaction is supported in a model discrimination analysis by DynaFit and provides an 
improved curve fit (Figure 2-5). Although incubation of DXP synthase with D-GAP in 
the absence of pyruvate does not result in new product formation or enzyme-dependent 
depletion of D-GAP, a rapid equilibrium, random sequential mechanistic model 
considering the reversible substrate inhibition by D-GAP provides significantly improved 







Figure 2-5. Global non-linear regression analysis of control data for a random 
sequential mechanism 
(21)
. Panels A-C: Random sequential mechanism. Panels B and E: 
Varying D-GAP at fixed pyruvate concentrations: 18.0 (●), 24.0 (■), 36.0 (▲),  48.0 (▼), 
60.0 (♦), 72.0 (►), 82.3 (◄), 94.0 (●) µM pyruvate.) Panels C and F: Varying pyruvate 
at fixed D-GAP concentrations: 12.3 (●), 24.5 (■), 36.8 (▲),  49.0 (▼), 73.5 (♦), 98.0 
(►), 122.5 (◄), 146.0 (●) µM D-GAP. Panels D-F: Global fit analysis of kinetic data for 
a random sequential mechanism considering substrate inhibition by D-GAP 
(nonproductive reaction) and pyruvate (formation of acetolactate). 
 
2.2. Pyruvate analogs inhibit E. coli DXP synthase. 
2.2.1. Inhibition of DXP synthase by β-fluoropyruvate and methylacetylphosphonate 
β -Fluoropyruvate and phosphonate analogs of 2-oxo acids have been extensively 






Unlike β-fluoropyruvate, which undergoes a catalytic step to release carbon dioxide and 
subsequently eliminates fluoride following activation by ThDP, MAP is incapable of 
undergoing decarboxylation (Figure 2-6). 
 
 
Figure 2-6. β-Fluoropyruvate and MAP shown as pyruvate mimics in a mechanism 
requiring ternary complex formation. A) DXP synthase is presumed to adopt a “post-
decarboxylation” state similar to the C2-α carbanion formed upon decarboxylation of 
LThDP. B) DXP synthase is presumed to adopt a “pre-decarboxylation” state following 
the formation of the phosphono-2-lactyl-ThDP (PLThDP) intermediate. E, ThDP-bound 
enzyme; Pyr, pyruvate; G, D-GAP. 
 
Pyruvate analogs β-fluoropyruvate and methylacetylphosphonate (MAP) were 




mechanism favored by the global fit. For a random sequential mechanism, β-
fluoropyruvate and MAP are predicted to behave as competitive inhibitors with respect to 
pyruvate but will exhibit a noncompetitive profile with respect to D-GAP 
(24-26)
. Initial 
rates of DXP formation were monitored using the IspC coupled assay at sub-saturating, 
varied concentrations of one substrate, at fixed concentrations of the second substrate and 
in the presence of varying inhibitor concentrations (β-fluoropyruvate or MAP). The 
results (Figure 2-7) show that MAP is a competitive inhibitor with respect to pyruvate 
(apparent Ki
MAP
 = 715 ± 108 nM). When D-GAP is the varied substrate, the trend is 
noncompetitive, as expected for a random sequential mechanism. A similar inhibition 
profile was observed for β-fluoropyruvate (Ki 
β-FPYR
 = 430 ± 135 nM) (Figure 2-8). 
 
 
Figure 2-7. Inhibition of DXP synthase by MAP 
(21)
.  A) The concentration of pyruvate 
was varied at a fixed concentration of D-GAP (120 µM), with increasing concentrations 
of MAP: 0 (○), 2 (●), 5 (□), 10 (■) µM. B) The concentration of D-GAP was varied at a 
fixed concentration of pyruvate (240 µM), with increasing concentrations of MAP: 0 (○), 






Figure 2-8. Inhibition of DXP synthase by β-fluoropyruvate 
(21)
. A) The concentration 
of β-fluoropyruvate was varied at a fixed concentration of D-GAP (120 µM), with 
increasing concentrations of MAP: 0 (○), 2 (●), 3 (□), 4 (■), 6 (△) µM. B) The 
concentration of D-GAP was varied at a fixed concentration of pyruvate (240 µM), with 
increasing concentrations of MAP: 0 (○), 2 (●), 4 (□), 6 (■)  µM. 
 
2.2.2. Inhibition by D-glyceraldehyde reveals important binding determinants. 
D-Glyceraldehyde was selected for inhibition studies as it is a commonly used D-
GAP analog 
(6, 14, 15, 38)
. A random sequential kinetic mechanism predicts this analog to 
exhibit a competitive inhibition pattern with respect to D-GAP in a Lineweaver-Burk 
analysis and a noncompetitive profile with respect to pyruvate 
(24-26)
. However, D -
glyceraldehyde exhibits a similar trend to MAP and β-fluoropyruvate, indicating 
competitive inhibition with respect to pyruvate (Figure 2-9, apparent Ki 
D-glyceraldehyde
 = 
3.2 ± 0.4 mM). It has been suggested that D-glyceraldehyde also acts as a substrate 
inhibitor competing for the pyruvate binding site at considerably higher concentrations 
(6)
.  




this substrate analog, suggesting D-glyceraldehyde may not be an ideal alternative 
substrate for D-GAP in mechanistic studies of DXP synthase. 
 
Figure 2-9. Inhibition of DXP synthase by D-glyceraldehyde 
(21)
. A) The concentration 
of pyruvate was varied at a fixed concentration of D-GAP (120 µM), with increasing 
concentrations of glyceraldehyde: 0 (○), 2.5 (●), 5 (□), 10 (■), 15 (△)  mM. B) The 
concentration of D-GAP was varied at a fixed concentration of pyruvate (240 µM), with 
increasing concentrations of glyceraldehyde: 0 (○), 2.5 (●), 10 (■), 15 (△) mM. 
 
2.3. Exploring the mechanism of DXP synthase from Mycobacterium tuberculosis, 
Yersinia pestis, and Salmonella typhimurium.  
2.3.1. Overexpression and purification of pathogenic DXP synthase. 
Overexpression plasmids encoding the dxs gene from Y. petis and S. typhimurium 
were provided by Dr. Misty Kuhn and Prof. Wayne Anderson (Center for Structural 
Genomics of Infectious Diseases, Northwestern Feinberg School of Medicine).  
The M. tuberculosis DXP synthase (dxs1) overexpression plasmid was generated as 
previously reported 
(15)
, with one exception: 5% dimethyl sulfoxide (DMSO) was added 
to the polymerase chain reaction (PCR) amplification from H37Rv genomic DNA 




overexpression and purification of Dxs1 required considerable troubleshooting. Initially, 
the method reported by Bailey et al 
(15)
 was pursued. Unfortunately, the majority of 
protein produced using this overexpression protocol was insoluble. As most M. 
tuberculosis proteins are difficult to overexpress and purify in the E. coli model system, 
this outcome was not unsurprising. In fact, many researchers address this problem 
through the use of an M. smegmatis strain that is engineered for overexpression of M. 
tuberculosis proteins 
(39, 40)
. In order to address solubility issues for heterologous 
expression in E. coli, a number of growth conditions were modified. Overexpression was 
investigated from a variety of cell types (see below) at 15°C, 25°C, and 37°C. Induction 
with IPTG was pursued for 5, 16, and 24 hours at concentrations ranging from 0 to 1 
mM, with 25 µM being the lowest concentration tested. 
Further attempts were made to obtain soluble Dxs1 from various  E. coli 
overexpression cells lines, including: BL21 (DE3), single step KRX competent cells 
(Promega), BL21 Star plus pRIL cells (Agilent), Rosetta 2 cells (Merck), and Arctic 
Express cells (Agilent). The KRX cell line permits tighter control of the T7 RNA 
polymerase gene because it is under control of a rhamnose promoter, rather than IPTG. In 
contrast, T7 RNA polymerase is induced by IPTG, similar to the T7 promoter upstream 
from dxs1 in the other cell lines. By tightly controlling T7 RNA polymerase, premature 
expression of dxs1 should be negligible prior to induction. We also considered the 
possibility of codon bias, or the under-abundance of tRNAs required to express dxs1 in E. 
coli which would effectively stall expression. The BL21 Star plus pRIL cells are 
engineered to contain extra copies of genes that encode the tRNAs for AGG/AGA, AUA 




AUA, CUA, GGA, CCC, and CGG). Lastly, expression of Dxs1 was investigated in 
Arctic Express cells, as they have been optimized to grow at cooler temperatures (10-
13°C) and contain the Cpn60/Cpn10 chaperones from Oleispira antarctica, designed to 
overcome protein misfolding and insolubility. Attempts to overexpress Dxs1 in all cell 
types resulted in either lack of protein or largely insoluble protein, with the exception of 
expression in the Arctic Express cell line (Figure 2-10). For a detailed description of the 




Figure 2-10. Overexpression of E. coli DXP synthase and M. tuberculosis Dxs1 in 
Arctic Express cells. A) E. coli dxs-pET37b 
(30)
 was overexpressed in Arctic Express 
cells as a positive control. Lanes 2-4 show cells induced with 0.1 mM IPTG, lanes 5-7 
were not induced. 1) 2-212 kDa ladder 2) whole cell 3) soluble fraction 4) insoluble 
fraction 5) whole cell 6) soluble fraction 7) insoluble fraction. B) M. tuberculosis Dxs1 
overexpression. Lanes 2-4 show cells induced with 0.25 mM IPTG, lanes 5-7 were not 
induced. 1) 2-212 kDa ladder 2) whole cell 3) soluble fraction 4) insoluble fraction 5) 






Figure 2-11. Unsuccessful removal of Cpn60 chaperone during Dxs1 purification.  
 
Although soluble protein was obtained at a reasonable working concentration, 
there appeared to be ~15% contaminating Cpn60 in the final enzyme stock post 
purification and concentration. To ensure that the Cpn60 chaperone does not interfere 
with the activity of Dxs1, a dose-response experiment was carried out in which Cpn60 
was added up to 1 µM; Cpn60 does not appear to exert any effects at these 
concentrations. However, for these experiments the Dxs1 stock solution already 
contained 15% Cpn60. In attempts to remove Cpn60 from Dxs1 stock solutions, the 
enzyme was purified in the presence or absence of 10 mM adenosine-triphosphate (ATP) 
and 150 mM potassium chloride (KCl) prior to binding of the protein to the Ni-NTA 
resin (Pierce). These concentrations of ATP and KCl have been reported to remove 
Cpn60 during the Ni-NTA column purification process 
(41)
. However, this treatment did 
not remove the Cpn60 chaperone from Dxs1 and also caused apparent 40% reduction in 
the initial rate of Dxs1. This is in agreement with experiments that show that ATP 
inhibits either DXP synthase and/or IspC in the coupled assay at concentrations as low as 








Figure 2-12. Adenosine-triphosphate (ATP) inhibits M. tuberculosis DXP synthase 
(Dxs1) and/or E. coli IspC. A) ATP inhibits the IspC coupled assay to monitor the Dxs1 
reaction. Conditions used: 100 mM HEPES, 1 mg/mL BSA, 5 mM NaCl, 2 mM MgCl2, 
2.5 mM TCEP, 1 mM TPP, 0.25 µM Dxs1,  1 µM IspC, 0.1 mM NAPDH, 84 µM 
pyruvate, 38 µM D-GAP  (2-fold Km substrates). B) ATP inhibits IspC. Condition used: 
100 mM HEPES, 0.15 mM DXP, 0.18 mM NADPH, 2 mM MgCl2, 50 nM IspC (Km 
substrates). 
 
2.3.2. Characterization of pathogenic DXP synthase enzymes. 
 Using a tri-buffered system (2-(N-morpholino)ethanesulfonic acid (MES),  
ethylmorpholine, diethanolamine) 
(42)
, the pH optimum was determined for M. 
tuberculosis DXP synthase. As changes in pH are also expected to reduce DXP 
reductoisomerase (IspC) activity, a discontinuous, HPLC-based assay was used for these 
studies 
(30)
 that permits direct detection of derivatized substrates and products. For M. 








Figure 2-13. pH-rate profile analysis of M. tuberculosis Dxs1. 
 
All DXP synthase enzymes were kinetically characterized using the enzyme 
coupled assays as previously described 
(21, 23)
 and the results are shown in Table 2-3.  The 
Km values obtained for Dxs1 from M. tuberculosis in this study (Km 
pyruvate
 = 81 ± 3 and 
Km 
D-GAP
 = 16.6 ± 0.9) (Figure 2-14) are comparable to those previously reported 
(15)




determined for DXP synthase from Y. pestis (Km 
pyruvate
 = 51 ± 6 and 
Km 
D-GAP
 = 26 ± 3) and S. typhimurium (Km 
pyruvate
 = 76 ± 19 and the Km 
D-GAP
 = 12 ± 1) 








pyruvate 51 ± 6 
112 ± 7 
D-GAP 26 ± 3 
M. tuberculosis 
pyruvate 81 ± 3 
48 ± 1 
D-GAP 17 ± 1 
S. enterica 
pyruvate 76 ± 19 
140 ± 20 
D-GAP 12 ± 1 
 
Table 2-3. Kinetic analysis of DXP synthase from Y. pestis, M. tuberculosis, and S. 











Figure 2-14. Kinetic characterization of DXP synthase enzymes (16). DXP synthase 
was obtained from A) Mycobacterium tuberculosis (Dxs1) B) Yersinia pestis C) 
Salmonella enterica serovar Typhimurium. The mean and standard deviation of three 
replicates was used to calculate Km, and the average of the three replicates (representative 




2.3.3. Homology modeling reveals differences near the M. tuberculosis Dxs1 ThDP 
cofactor binding site. 
To investigate structural similarities and differences amongst the pathogenic DXP 
synthase enzymes examined in this study, homology modeling was carried out (Lauren 
Boucher and Prof. Jürgen Bosch, Johns Hopkins University, School of Public Health) 
(Figure 2-15). Modeled to the D. radiodurans and E. coli DXP synthase crystal 
structures 
(2)
, both the S. typhimurium and Y. pestis enzymes appear to be structurally 
similar. However, the M. tuberculosis enzyme (Dxs1) presented challenges in modeling 
around the cofactor binding site, specifically around the Y177 residue (Figure 2-15). 
Interestingly, this position usually contains a bulky hydrophobic residue such as leucine, 
isoleucine, or methionine. This residue is believed to be responsible for maintaining the 
V-conformation of the cofactor that is universally conserved among all ThDP-dependent 
enzymes 
(43-45)
. In most other DXP synthase enzymes, this residue is an isoleucine. 
Previous reports suggest that this isoleucine residue and a neighboring isoleucine, both 
conserved in most ThDP enzymes, stabilize the thiazolium ring of the thiamine cofactor 
(2)








Figure 2-15. M. tuberculosis Dxs1 (green) modeled to D. radiodurans DXP synthase 
(dark blue) (Protein Data Bank code 2O1X 
(2)
). The Y177 residue presents challenges 
in modeling around the cofactor binding site. This residue is an isoleucine in DXP 
synthase from other organisms (I187 in the 2O1X structure shown here), and a bulky 




2.3.4. M. tuberculosis Dxs1 mutagenesis. 
Y177F displays a 1.8-fold reduction in catalytic activity compared to wild type 
(kcat = 6.3 ± 0.25 min
-1
), but substrate affinity is not affected (Table 2-4). It is possible 
that this mutation is interfering with the rate-limiting generation of the LThDP cofactor. 
Interestingly, although Y177I does not contain an aromatic ring, it displays higher 
turnover compared to the Y177F enzyme (kcat = 26.5 ± 1 min
-1
, Table 2-4). When the 
tyrosine residue is introduced on the E. coli enzyme at this position (I185Y), the Km value 
is comparable to wild type Dxs1 (Km 
D-GAP 
= 19.0 ± 4.6 µM; Km 
pyruvate 
= 42.0 ± 9.5 µM, 
Table 2-4), and wild type E. coli DXP synthase (Km 
D-GAP 
= 23.5 ± 1.7 µM; Km 
pyruvate 
= 
40.8 ± 4.6 µM) 
(46)
. However, the kcat for I185Y E. coli DXP synthase is approximately 5-




To examine the role of the tyrosine hydroxyl group, Y177S and Y177T were also 
evaluated (Table 2-4). Y177T displays a ~19-fold reduction in catalytic activity 
compared to wild type (kcat = 5.9 ± 0.3 min
-1
), but substrate affinity is not affected (Table 
2-4). In contrast, Y177S exhibits a 183-fold reduction in turnover (kcat = 0.66 ± 0.16 min
-
1
), but an apparent ~190-fold increase in substrate affinity for pyruvate, and ~1900-fold 
increase for D-GAP (Km 
D-GAP 
= 0.01 ± .002 µM; Km 
pyruvate 
= 0.22 ± 0.01 µM) (Table 2-
4). The relative size of serine and threonine are vastly different than the bulky tyrosine. 
Although a hydroxyl group is re-introduced in these variants, the smaller nature of these 
residues might not cover enough of a hypothetical distance to potentially hydrogen bond 
with an unknown partner in the same manner as wild type. As expected, introducing a 
charge at this position also results in a dramatic change in rate, as evidenced by the 
Y177E mutant (Table 2-4). 
From these results it can be concluded that in the absence of Tyr-177, a large 
hydrophobic residue is preferred over the smaller residues that contain a hydroxyl group. 
The role of the hydroxyl group in catalytic proton transfer can be better investigated 
using the CD method described in chapter 1, section 8 (see Discussion). Further, these 
results are in agreement with a recent study by Andrews et al 
(47)
, who reported crystal 
structures for variants at this position using the benzoylformate decarboxylase (BFDC) 
enzyme. They found that although a large hydrophobic residue was preferred for 















pyruvate 42.0 ± 9.48 110.7 ± 3.00 6.2 ± 1.6 
D-GAP 19.0 ± 4.56  117.0 ± 2.33  3.0 ± 0.3 
Y177E Dxs1 no activity at 1, 5, 10 µM enzyme and 0.1 - 2.0 mM substrates 
Y177F Dxs1 
pyruvate 70.7 ± 8.27 6.8 ± 0.23 0.78 ± 0.08 
D-GAP 7.32 ± 0.66 5.8 ± 0.31 0.10 ± 0.01 
Y177I Dxs1 
pyruvate 256 ± 51 28.1 ± 0.48 0.27 ± 0.05 
D-GAP 91.9 ± 16.7 24.6 ± 1.46 0.11 ± 0.02 
Y177S Dxs1 
pyruvate 0.22 ± 0.01 0.63 ± 0.13 13 ± 10 
D-GAP 0.01 ± 0.02 0.68 ± 0.18 2.8 ± 0.6 
Y177T Dxs1 
pyruvate 88 ± 22 5.2 ± 1.0 1.1 ± 0.8 
D-GAP 6.0 ± 3.8 6.6 ± 2.7 0.06 ± 0.02 
E. coli I185Y 
Dxs 
pyruvate 12.0 ± 5.5 24 ± 0.8 1.9 ± 0.9 
D-GAP 30.2 21.6 0.62 ± 0.15 
Y387F Dxs1 
pyruvate 46.5 ± 2.3 62.9 ± 0.8 0.43 ± 0.07 
D-GAP 142 ± 19 61.0 ± 4.8 1.3 ± 0.07 
Table 2-4. Kinetic parameters for M. tuberculosis Dxs1 enzymes. 
 
Y387 Dxs1 was also selected for mutagenesis, as this residue is believed to be 
involved in acceptor substrate binding and is the focus of a recent mutagenesis study on 
E. coli DXP synthase (Y392) 
(28)
. Using time-resolved CD spectroscopy and NMR 
experiments, it was found that Y392 appears to contribute to D-GAP affinity. However, 
Y392 is not absolutely required for the formation of the LThDP intermediate or its 
subsequent decarboxylation promoted by D-GAP 
(28)
. In this work, Y387F appears to 
effect D-GAP affinity on M. tuberculosis Dxs1, as there is a 7.5-fold increase in the Km 
for D-GAP for this enzyme variant (wild type Dxs1 Km 
D-GAP 
= 19.0 ± 4.6 µM; Y387F 
Dxs1 Km 
D-GAP 
= 142 ± 20 µM, Table 2-4). This is comparable to the 9-fold increase that 






23.5 ± 1.7 µM; Y392F Km 
D-GAP 
= 210 ± 20 µM; Y392F Km 
D-GAP 





Despite its potential as an anti-infective target, selective inhibitors of DXP 
synthase are lacking, and reports on the kinetic mechanism are conflicting. The 
development of selective inhibitors requires knowledge of the characteristics that 
distinguish this enzyme from other ThDP-dependent enzymes. The work in this chapter 
takes important steps toward understanding the unique mechanism of DXP synthase. In 
addition to providing insight regarding order of substrate binding, the results of kinetic 
analysis suggest pronounced substrate inhibition by D-GAP (Figure 2-4). The observed 
inhibition by both natural substrates at reasonably low concentrations underscores the 
complexity of substrate equilibrium binding profiles and highlights a promiscuous active 
site of DXP synthase. The discrepancies between the trends in the double-reciprocal 
analysis reported here and those reported previously 
(6, 8)
  may be explained by 
differences in reaction conditions. As substrate inhibition is most evident at lower 
concentrations of the varied substrate, it is anticipated that the subtle inhibitory effects of 
pyruvate and D-GAP are not observed under conditions where more pronounced 
inhibition by citrate buffer or removal of D-GAP by reaction with Tris buffer is taking 
place. 
Unexpectedly, we determined that D-glyceraldehyde is competitive with pyruvate 
but not with D-GAP (Figure 2-9). Although D-glyceraldehyde has been used previously 
as an alternative substrate for D-GAP 
(6, 14, 15, 38)




glyceraldehyde can compete for the pyruvate binding site as a substrate inhibitor at high 
millimolar concentrations 
(6)
. Here, we have shown that removal of the phosphoryl group 
of D-GAP changes the binding mode of the aldehyde such that it fails to compete for the 
D-GAP binding site. This result highlights the impact of the phosphoryl moiety on 
substrate recognition and binding and may underscore the importance of using the natural 
substrate D-GAP for mechanistic studies of this enzyme. In addition, this result further 
highlights the promiscuous active site of this enzyme, suggesting opportunities to develop 
selective inhibitors.  
Additionally, methylacetylphosphonate (MAP), a catalytically unreactive analog 
of pyruvate, was prepared to aid in elucidation of substrate binding order on the GAP 
binding preferences. MAP is a well characterized inhibitor of many ThDP-dependent 
enzymes 
(31-37)
. MAP exhibits a clear competitive mode of inhibition with respect to 
pyruvate, and a noncompetitive mode of inhibition with respect to D-GAP (Figure 2-7). 
The observed potent inhibition of DXP synthase by this pyruvate analog raises the 
intriguing ideas about the utility of acetyl phosphonate derivatives as selective inhibitors 
targeting the unique conformations of this mechanistically distinct ThDP-dependent 
enzyme, a concept further detailed in Chapter 3. 
While this work was in progress, a study describing single- molecule force 
spectroscopy for the identification of novel DXP synthase inhibitors was reported 
(7)
. The 
method allows measurement of adhesion forces between immobilized substrates and 
enzyme. The authors suggest a possible dissociation of substrate recognition properties 
and substrate transformation properties that could permit the use of this catalytically less 




substrate turnover. Interestingly, Sisquella et al. reported binding of GAP tethered 
through the phosphoryl moiety and enhancement of its affinity for the enzyme in the 
presence of soluble pyruvate. This is particularly interesting, in light of our finding that 
removal of the phosphoryl moiety inverts the binding mode of the acceptor aldehyde. It is 
possible that immobilization of DXP synthase effects changes in the active site that 
promote the binding of an unnatural immobilized substrate. Alternatively, it is 
conceivable that the immobilized monoanionic phosphate diester binds in a similar 
manner to D-GAP, suggesting that an acceptor substrate bearing a monoanionic 
substituent is sufficient to retain the natural binding mode.  
The unequivocal distinction between the previously proposed mechanisms 
(6, 7)
  
and the random sequential mechanism proposed by our laboratory is difficult on the basis 
of kinetic analysis alone. However, the kinetic analyses presented in this work do argue 
against ping-pong or rapid equillibirum ordered mechanisms, yet support either a rapid 
equilibrium, random sequential mechanism or an ordered mechanism, in which pyruvate 
binds tightly and essentially irreversibly.  Both of these mechanisms require the 
formation of a ternary complex. Molecular docking studies provide additional support for 
the formation of this ternary complex; Deinococcus radiodurans DXP synthase 
(2)
 
(Protein Data Bank code 2O1X) can easily accommodate both substrates near the C2 
position of ThDP (Figure 2-16) because the active site of DXP synthase is large. In 
agreement with this, our group has reported active site calculations indicating that the 
active site of DXP synthase is 2.5-fold larger than other ThDP-dependent enzymes, 
pyruvate dehydrogenase and transketolase 
(48)
. This docking analysis also suggests that 




radiodurans DXP synthase R480 and R423.  Subsequent work by our lab has used E. coli 
DXP synthase to confirm the involvement of R478 (analogous to R480) and R420 







. Pyruvate (A) and D-GAP (B) docked to the active site of D. 
radiodurans DXP synthase. Each substrate apparently accesses the active site without 
blocking access of the other (C). 
 
Reanalysis of the kinetic data with respect to natural substrates provides 
additional insight. A global non-linear regression analysis supports a random sequential 
mechanism over an ordered mechanism with essentially irreversible pyruvate binding 
(Figure 2-5). However, this global non-linear regression analysis was executed with the 
idea that for E. coli DXP synthase the Kd 
D-GAP is comparable to the Km 
D-GAP, based on 
tryptophan fluorescent studies 
(21)
. Subsequent studies have pointed to the instability of 
wild type E. coli DXP synthase and variants as probes in tryptophan fluorescence 
experiments. Thus, total protein fluorescence has been utilized to re-evaluate dissociation 
constants, leading to determination of a higher Kd 
D-GAP (2.0 ± 0.5 mM) 
(28)
. This value is 
significantly higher than the Km 
D-GAP (23.5 ± 1.7 µM) 
(21)
. The Kd 
pyruvate measured using 
total protein fluorescence is higher than the  Km 
pyruvate  (Kd 




pyruvate = 49 ± 8 µM) 
(21, 28)
. These results suggest that while each substrate binds to DXP 
synthase, the E-pyruvate complex is apparently formed more readily that the E-GAP 
complex, supportive of a random sequential, preferred order mechanism 
(21)
. 
Our results raised intriguing questions about the role of D-GAP binding in steps 
leading to the generation of the nucleophilic C2-α carbanion (Figure 2-17), including the 
ionization and tautomerization states of ThDP and timing of pyruvate activation. In all 
other ThDP-dependent enzymes that catalyze decarboxylation via a ping-pong 
mechanism, the aminopyrimidine ring of ThDP tautomerizes upon binding of the first 
substrate to promote the formation of a short lived predecarboxylation complex 
(49)
.  In 
the unique case of DXP synthase, accelerated decarboxylation of LThDP appears to 
occur only in the presence of the acceptor substrate D-GAP 
(6)
 ; however, it was not 
known whether D-GAP binding is required for tautomerization of the cofactor and 
formation of LThDP or if binding of D-GAP promotes decarboxylation of LThDP and 
formation of the C2-α carbanion. 
In collaboration with Dr. Frank Jordan (Rutgers University, Department of 
Chemistry), the activation and tautomerization of the thiamin cofactor were studied using 
stopped flow circular dichroism (CD) to monitor enzyme events, and proton NMR was 
used to monitor ThDP-bound intermediates after release from the enzyme under acidic 
conditions 
(27)
. In this study, formation of the LThDP intermediate was observed in the 
absence of D-GAP (Figure 2-17), and LThDP appears to be remarkably stable on DXP 
synthase, a characteristic that is unique among ThDP-dependent enzymes. On other 
ThDP-dependent enzymes, the LThDP intermediate is “extremely short lived and 




under steady state turnover or single turnover conditions almost impossible” 
(27)
. It was 
also discovered that D-GAP promotes a 600-fold rate increase in CO2 release. Both of 
these findings support a mechanistic model in which a ternary complex is formed 
between the enzyme and both substrates prior to decarboxylation, and this is unique 
among ThDP-dependent enzymes.  
 





Finally, although steady state kinetic analysis of E. coli, Y. pestis, S. typhimurium, 
and M. tuberculosis DXP synthase enzymes suggest these behave similarly, M. 
tuberculosis Dxs1 is predicted to have subtle structural differences around the ThDP 
cofactor binding site, apparently due to the Y177 residue (Figure 2-15). The CD method 
described above should prove to be especially useful for studying the role of this 
hydroxyl group during formation of LThDP and its subsequent decarboxylation on M. 
tuberculosis Dxs1. Tryptophan fluorescence analysis could further inform on 
conformational changes that take place near the ThDP binding pocket during formation 




 In summary, the data presented in this chapter provide evidence for ternary 
complex formation in the kinetic mechanism of DXP synthase, and DXP synthase 
enzymes from a variety of different bacterial species exhibit similar kinetic behavior. 
Either substrate is capable of binding to the active site, and both are required prior to 
catalysis in decarboxylation and carboligation steps. These results are in striking contrast 
to all other ThDP-dependent enzymes, which supports the idea that it will be possible to 
develop selective inhibitors targeting this distinct ThDP-dependent enzyme toward the 




General Methods. Unless otherwise noted, all reagents were obtained from commercial 
sources. Primers were purchased from Integrated DNA Technologies. 
Spectrophotometric analyses were performed on a Beckman DU800 UV/Visible 
spectrophotometer. E. coli wild type DXP synthase and variants were purified as 
described previously 
(21, 30)
. E. coli DXP reductoisomerase (IspC) was also prepared as 
described previously 
(30)
. Molecular docking studies were performed using the program 




Cloning, overproduction, and purification of M. tuberculosis DXP synthase (Dxs1). 
Rv2682c was PCR amplified from H37Rv genomic DNA and ligated into the pET28a+ 
vector (Novagen), as previously reported 
(15)
. dxs1-pET28a+ was then transformed into 




expression plasmid were grown in LB broth at 30°C with shaking at 220 rpm until OD600 
= 0.8, then cooled for 30 minutes on ice. After cooling, cultures were induced with 0.25 
mM ispropylthiogalactoside (IPTG), and growth was continued with shaking at 13°C for 
24 hours. Cells were harvested by centrifugation at 8 000 rpm for 10 min, and the cell 
pellet was stored at –20°C. The frozen cell pellet was suspended in lysis buffer (3 mL per 
gram of cells) containing 50 mM Tris HCl (pH =8), 5 mM MgCl2, 10% glycerol v/v, 5 
mM mM  β-mercaptoethanol (BME), 1 mM PMSF, 1 mM ThDP, 1x protease inhibitor 
cocktail, 100 mM NaCl, and 0.01% Igepal-CA630. Cells were lysed by sonication and 
centrifuged for 45 minutes at 18 000 rpm to pellet cell debris. The supernatant was 
incubated with nickel-nitrilotriacetic (NTA) acid resin in 20 mM imidazole at 4°C for 2 
hours, and Dxs1 was eluted from the resin over a stepwise gradient of 5 to 500 mM 
imidazole. Fractions containing Dxs1 (as determined by 10% SDS-PAGE) were 
combined and subjected to dialysis overnight at 4°C against 1 liter of 50 mM Tris (pH 
8.0), 10 mM MgCl2, 10% glycerol, 1 mM ThDP, and 100 mM NaCl. A second dialysis 
was carried out against 1 liter of 50 mM Tris (pH 8.0), 10 mM MgCl2, 10% glycerol, 1 
mM ThDP, and 100 mM NaCl and 1 mM for an additional 4 h. After dialysis, protein 
concentration was determined using the Bio-Rad Protein Assay with bovine serum 
albumin as a standard (yield 1.0 mg/liter of culture). Protein was flash frozen in liquid 
nitrogen and stored at -80 °C. 
 
Cloning, overproduction, and purification of Yersinia pestis, and Salmonella 
typhimurium DXP synthase. The Y. pestis and S. typhimurium DXP synthase genes 




as previously described 
(51, 52)
 and the resulting plasmids were transformed into Single 
Step KRX competent cells (Promega). Cells harboring the overexpression plasmid were 
grown in TB broth containing 100 µg/mL ampicillin, 34 µg/mL chloramphenicol, and 
0.1% L(+)arabinose. After growth reached OD600 = 0.6 at 37°C, the cultures were cooled 
to room temperature and induced with 0.5 mM IPTG and 0.25% rhamnose, and shaking 
was continued for 16 hours. Cells were harvested, lysed, and purified using the same 
method as described for M. tuberculosis Dxs1. 
 
Overproduction and Purification of IspC 
(30)
. E. coli BL21 cells harboring ispC-
pET16b were grown to A600 = 0.6 and induced with isopropylthiogalactoside (100 µM) at 
37°C. Shaking was continued for 5 h, and the cells were harvested at 4°C and stored 
overnight at -20 °C. Thawed cells were resuspended in protein purification buffer (25 
mM Tris, pH 8.0, 400 mM NaCl, 10% glycerol), lysed by ultrasonication, and cell debris 
was removed by centrifugation at 4 °C. The supernatant was incubated with nickel-
nitrilotriacetic acid resin in 20 mM imidazole at 4 °C for 2 h, and IspC was eluted from 
the resin over a stepwise gradient of 5 to 500 mM imidazole. Fractions containing IspC 
(as determined by 10% SDS-PAGE) were combined and subjected to dialysis overnight 
at 4 °C against 1 liter of 50 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA, and 10% 
glycerol. A second dialysis was carried out against 1 liter of 50 mM Tris, pH 8.0, 100 
mM NaCl, 1 mM EDTA, 10% glycerol, and 1 mM β-mercaptoethanol for an additional 4 
h. After dialysis, protein concentration was determined using the Bio-Rad Protein Assay 
with bovine serum albumin as a standard (yield 33 mg/liter of culture). Protein was then 





Kinetic Analyses. Wild type DXP synthase activity was measured 
spectrophotometrically using IspC as a coupling enzyme as reported previously 
(23)
  with 
minor modifications 
(21)
. The concentration of D-GAP in stock solutions was determined 
as reported previously 
(30)
. DXP synthase reaction mixtures containing HEPES (100 mM, 
pH 8.0), 1 mg/mL BSA, 2 mM MgCl2, 2.5 mM tris(2-carboxyethyl)phosphine, 1 mM 
ThDP, 100 µM NADPH, 1 µM IspC, D,L-GAP, and pyruvate were preincubated at 37 °C 
for 5 min. DXP synthase (100 nM) was added to initiate each reaction, and the rate of 
NADPH depletion in the coupled step was monitored spectrophotometrically at 340 nm 
at 37°C. The rate of NADPH depletion was used to calculate initial rates of DXP 
formation. All experiments were performed in triplicate. Double reciprocal analysis was 
performed using GraFit from Erithacus Software (version 7). Non-linear regression 
analysis of initial velocities and model discrimination analyses were performed using the 
computer simulation software DynaFit (version 3.28.06) 
(29)
. The pH-rate profile for M. 





Inhibition Studies. DXP synthase reaction mixtures containing 100 mM HEPES buffer, 
pH 8.0 (described above) were preincubated at 37°C for 5 min with β-fluoropyruvate (2, 
3, 4, and 6 µM), MAP (2, 5, 10, and 12 µM), or D-glyceraldehyde (2.5, 5, 10, and 15 
mM). Inhibition of the coupling enzyme, IspC, by β-fluoropyruvate, MAP, or D-
glyceraldehyde was not observed up to 0.5 mM inhibitor. DXP synthase (100 nM) was 




spectrophotometrically at 340 nm at 37°C. All experiments were performed in triplicate. 
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Chapter 3. Development and evaluation of selective inhibitors of DXP synthase. 
 
Introduction:  
Although numerous efforts have been made to identify inhibitors of pathogen 
isoprenoid biosynthesis, few potent inhibitors of the MEP pathway have been reported. 
Fosmidomycin potently inhibits the second enzyme in the pathway (IspC), and is the only 
MEP pathway inhibitor under clinical evaluation 
(1-3)
.  A previous study by Mai et al 
(4)
 
attempted to develop selective M. tuberculosis DXP synthase inhibitors using a target-
based approach starting from a known, thiamin-based transketolase inhibitor, 3-(4-
chloro-phenyl)-5-benzyl-4H-pyrazolo[1,5-a]pyrimidin-7-one 
(4)
. While the most potent 
enzyme inhibitor in this study showed in vivo activity against M. tuberculosis cultures 
(IC50 7.6 = µM), these thiamin analogs also exhibited toxicity against mammalian cells, 
suggesting off-target activity against mammalian ThDP-dependent enzymes. This 
observation underscores the challenge in gaining selectivity of inhibition at the cofactor 
binding site which is highly conserved within the ThDP-dependent enzyme class 
(5)
. 
In principle, selective inhibition can be achieved by targeting the unique kinetic 
mechanism and/or conformational dynamics of DXP synthase. As outlined in Chapter 2, 
DXP synthase follows a unique kinetic mechanism in the ThDP-dependent class, 
requiring a ternary complex prior to catalysis for C-C bond formation 
(6, 7)
. Our group 
also demonstrated flexibility in the active site of E. coli DXP synthase toward non-polar 
acceptor substrates, including aliphatic aldehdyes 
(8)
. On the basis of the relaxed 
specificity and the knowledge that DXP synthase requires formation of a ternary 




chain will create an unnatural bisubstrate analog that exhibits high affinity for a unique 
DXP synthase conformation that accommodates both substrates. In this work, initial 
studies evaluated commercially available bisubstrate analogs as DXP synthase inhibitors. 
These compounds incorporate a carboxylate group as the GAP mimic (the natural 
acceptor substrate) and α-keto acids as the pyruvate mimic (the donor substrate) (Figure 
3-1, series A).  
 
 
Figure 3-1. Bisubstrate analogs of DXP synthase 
(9)
. A) carboxylate bisubstrate analogs 
B) analogs linked through an acyl phosphonate group C) analogs linked through 
phosphonate ester group. 
 
Additionally, analogs that incorporate elements of the donor substrate, pyruvate, 
and a non-polar acceptor substrate were also evaluated. Methylacetylphosphonate (MAP) 




a well-characterized inhibitor of ThDP-dependent enzymes that utilize pyruvate as 
substrate 
(10-15)
.  As discussed in Chapter 2, we have investigated the inhibitory activity of 
MAP against DXP synthase during studies to elucidate the mechanism of this enzyme 
(see 2.2.1) 
(7)
. The observation that MAP potently inhibits DXP synthase prompted 
speculation about the potential utility of alkylacylphosphonates as bisubstrate analogs for 
selective inhibition of DXP synthase. Two compound series were envisioned that 
incorporate an acylphosphonate group as the pyruvate mimic (Figure 3-1). Modification 
of either the acyl or alkyl groups of the phosphonate could mimic a non-polar acceptor 
substrate and test the importance of acylphosphonate orientation in bisubstrate analogs. 
Although DXP synthase exhibits relaxed substrate specificity for non-polar acceptor 
substrates, α-ketoacids modified at the acyl position are poor alternative donor substrates 
for this enzyme 
(8)
.   On this basis, we hypothesized that phosphonates modified at the 
alkyl position (Figure 3-1, series B) should have more potent inhibitory activity against 
DXP synthase compared to phosphonates modified at the acyl position (Figure 3-1, 
series C). This chapter will describe the evaluation of commercially available 
dicarboxylates, as well as the design and synthesis of acetylphosphonate analogs in order 
to achieve selective inhibition against DXP synthase. 
 
Results 
3.1. Dicarboxylates are poor bisubstrate inhibitors of E. coli DXP synthase. 
Bisubstrate analogs bearing two carboxylate groups as mimics of GAP and 
pyruvate (Figure 3-1, series A) were evaluated as inhibitors of E. coli DXP synthase 




suitable mimic for phosphate in this system. Substrate specificity studies carried out 
using carboxylate-bearing aldehydes (Leighanne Brammer Batsa, PhD) also reach this 
conclusion. For future mechanistic studies using bisubstrate analogs, the more 
challenging synthesis of a phosphate-bearing (GAP mimic) bisubstrate analog could be 
pursued.  It should also be noted that oxaloacetate (2) exhibited time dependent 
inhibition. However, inhibition of the enzyme was first determined using an IspC-
coupled assay
 (2, 7)
 and after evaluating activity using a discontinuous HPLC based assay
 
(8)
, it was determined that oxaloacetate is in fact a poor alternative donor substrate for 
DXP synthase, and further studies were not pursued. 
 
compound # slow inhibition? IC50   
mesoxalic acid 1 no > 3 mM  
oxaloacetate 2 yes N.D.* 
alpha-ketoglutarate  3 no > 3 mM 
oxoadipic acid 4 no > 3 mM  
2-oxoheptanedioc acid 5 yes 2 ± 0.9 mM  
 
Table 3-1. Carboxylate bisubstrate analogs are poor inhibitors of E. coli DXP 
synthase. *alternative substrate. For slow inhibition, DXP synthase was incubated with 
the dicarboxylate analog for 5 minutes and initiated with D-GAP. 
 
3.2. Acetylphosphonates selectively inhibit E. coli DXP synthase.  
Alkylacylphosphonates 6-8 were evaluated as inhibitors of E. coli DXP synthase 
using a spectrophotometric, coupled assay
 (2, 7)
. As shown in mechanistic studies of DXP 
synthase 
(7)
, MAP (6) is a potent competitive inhibitor against pyruvate (Ki 
MAP
 = 0.96 ± 




3-1) results in dramatic reduction of inhibitory activity against DXP synthase (Table 3-
2), highlighting the importance of the small acetyl group in this pyruvate mimic. In 
contrast, compounds bearing a non-polar acceptor substrate mimic at the 
alkylphosphonate group (6-8, Figure 3-1) are potent inhibitors of DXP synthase. 
Ethylacetylphosphonate (EAP, 7) and butylacetylphosphonate (BAP, 8) exhibit 
comparable inhibitory activity to MAP, with Ki values of 6.7 ± 0.03 µM (Figure 3-3) and 
5.6 ± 0.8 µM (Figure 3-4), respectively (Table 3-2). Similarly, both compounds show a 
competitive mode of inhibition with respect to pyruvate.  
The goal of this work is to demonstrate selective inhibition of DXP synthase over 
other members of the ThDP-dependent class of enzymes. Compounds bearing an 
acylphosphonate mimic of pyruvate are not expected to exhibit inhibitory activity against 
transketolase as this enzyme does not recognize pyruvate as a substrate. As expected, 
none of the compounds reported here shows inhibitory activity against transketolase at 
concentrations up to 1 mM (Table 3-2). In contrast, pyruvate dehydrogenase E1 subunit 
(PDH) uses pyruvate as its natural substrate, and the pyruvate analogs MAP and the 
related phosphinates are known inhibitors of this enzyme 
(10, 11, 14-16)
. However, the kinetic 
mechanism of PDH is distinct from DXP synthase, and small hydrogen and methyl 
phosphinates show a marked increase in inhibitory activity against PDH compared to 
MAP. We hypothesized that EAP and BAP may exhibit high affinity for DXP synthase 
which is known to accommodate both substrates in its active site prior to decarboxylation 
of pyruvate; however, these sterically demanding analogs should be less potent inhibitors 
of PDH. Indeed, all three alkylacylphosphonates tested, MAP, EAP and BAP, are 




values against PDH of 29.9 ± 12.6 µM, 46.6 ± 1.9 µM and 335.4 ± 7.9 µM, respectively 
(Table 3-2). Even the smallest alkylacylphosphonate, MAP, exhibits selective inhibition 




 = 31). Selectivity of inhibition increases with 
increasing chain length, as demonstrated by the greatly reduced inhibitory activity of 




 = 60). Compounds 9-
11 bearing modified acyl groups are not inhibitors of porcine PDH at concentrations up to 
1 mM (Table 3-2). 
 
 
Figure 3-2. Competitive inhibition by methylacetylphosphonate (MAP) 
(9)
. A) DXP 
synthase. The concentration of pyruvate was varied with increasing concentrations of 
MAP: 0 (○), 2.5 (●), 5 (□), and 10 (■) µM. B) E1 subunit of pyruvate dehydrogenase. 
The concentration of pyruvate was varied with increasing concentrations of MAP: 0 (○), 






Figure 3-3. Competitive inhibition by ethylacetylphosphonate (EAP) 
(9)
. A) DXP 
synthase. The concentration of pyruvate was varied with increasing concentrations of 
EAP: 0 (○), 10 (●), 25 (□), and 50 (■) µM. B) E1 subunit of pyruvate dehydrogenase. 
The concentration of pyruvate was varied with increasing concentrations of EAP: 0 (○), 
50 (●), 100 (□), and 200 (■) µM. 
 
 
Figure 3-4. Competitive inhibition by butylacetylphosphonate (BAP) 
(9)
. A) DXP 
synthase. The concentration of pyruvate was varied with increasing concentrations of 
BAP: 0 (○), 10 (●), 25 (□), and 50 (■) µM BAP. B) E1 subunit of pyruvate 
dehydrogenase. The concentration of pyruvate was varied with increasing concentrations 





Figure 3-5. Competitive inhibition of DXP synthase by methyl 
proprionylphosphosphate (4, MPP) 
(9)
. The concentration of pyruvate was varied with 
increasing concentrations of MPP: 0 (○), 250 (●), 500 (□), and 750 (■) μM. 
 
E. coli DXP synthase porcine PDH S. cerevisiae 
(Km = 40.8 ± 4.6 µM) (Km = 54.0 ± 5.3  µM) transketolase 
compound Ki  (µM) compound Ki  (µM) compound Ki 
1 (MAP) 1.1 ± 0.2  1 (MAP) 38.5 ± 5.5 1 (MAP) > 1 mM 
2 (EAP) 6.4 ± 0.5 2 (EAP) 44.1 ± 5.3 2 (EAP) > 1mM 
3 (BAP) 5.5 ± 0.9 3 (BAP) 291.8 ± 30.7  3 (BAP) > 1 mM 
4 258.4 ± 67.8  4 > 1 mM 4 > 1 mM 
5 > 1 mM 5 > 1 mM 5 > 1 mM 
6 > 1 mM 6 > 1 mM 6 > 1 mM 
 
Table 3-2. Inhibition of ThDP-dependent enzymes: E. coli DXP synthase, porcine 




3.2.1. Butylacetylphosphonate (BAP) inhibition is conserved among pathogenic DXP 
synthase. 
Our work has established alkyl acetylphosphonates as selective inhibitors of E. 
coli DXP synthase 
(9)




ThDP-dependent enzyme on the basis of differences in substrate usage and mechanism. 
In order to ensure alkylacetylphosphonates have broad spectrum activity against a variety 
of bacterial DXP synthase, inhibitory activity of BAP was characterized against DXP 
synthase from M. tuberculosis, Y. pestis, and S. typhimurium (Figure 3-6). In all cases, 
low micromolar inhibitory activity of BAP is observed that is comparable to the 
inhibitory activity of BAP against E. coli DXP synthase.  As expected, the mode of 
inhibition is competitive with respect to pyruvate and noncompetitive with respect to D-
GAP (for M. tuberculosis DXP synthase, Ki
BAP
 = 4 ± 2 µM; for Y. pestis DXP synthase, 
Ki
BAP
 = 7.5 ± 0.9 µM; for S. enterica DXP synthase, Ki
BAP







Figure 3-6. Enzyme inhibitory activity of BAP 
(17)
. Representative inhibition kinetics 
are shown for BAP with respect to pyruvate or D-GAP against DXP synthase from A) M. 
tuberculosis B) Y. pestis C) S. enterica. The mean and standard deviation of three 








This work shows that alkylacetylphosphonates selectively target DXP synthase 
(9)
. 
Presumably these analogs exhibit high affinity for a DXP synthase active site that 
uniquely accommodates both donor and acceptor substrates. The results indicate that 
modification of the acetyl group abrogates inhibitory activity of acetylphosphonates, 
consistent with the observation that acyl-modified α-ketoacids are not substrates for DXP 
synthase 
(8)
. However, lengthening the carbon chain of the alkyl phosphonate produces 
inhibitors with comparable activity to MAP. These analogs are considerably less potent 
inhibitors of porcine PDH and do not exhibit measurable inhibitory activity against 
transketolase. We also characterized the inhibitory activity of butylacetylphosphonate 
(BAP) against pathogenic DXP synthase to demonstrate comparable inhibitory activity, 
an important finding if acetylphosphonates are to be developed as broad spectrum anti-
infectives. BAP displays low micromolar inhibitory activity against DXP synthase from 
M. tuberculosis, S. enterica, and Y. pestis, 
(17)
 and this is consistent with the idea that 
BAP targets a mechanism common to all pathogenic DXP synthase enzymes, but distinct 
from mammalian ThDP-dependent enzymes. Not surprisingly, BAP acts as a competitive 
inhibitor with respect to pyruvate in all cases, indicating that the acetylphosphonate 
moiety of BAP acts as a pyruvate mimic in this unnatural bisubstrate analog. 
Taken together, these results are consistent with a unique inhibition mechanism in 
ThDP-dependent enzymology, and suggest an exciting new direction for the development 
of a new class of inhibitors targeting early-stage isoprenoid biosynthesis. Toward this 
end, structure activity relationship (SAR) studies will be carried out in order to improve 




substrate specify and reaction promiscuity will provide a foundation for SAR 
(8, 18)
. For 
example, it has been shown that aromatic nitroso compounds are high affinity acceptor 
substrates of E. coli DXP synthase 
(18)
. In future studies, high affinity aromatic elements 




General Methods. Pyruvate dehydrogenase from porcine heart and transketolase from 
baker’s yeast (S. cerevisiae) were obtained from Sigma Aldrich. 
 
 Kinetic Analyses. DXP synthase activity was measured spectrophotometrically using 
IspC as a coupling enzyme as previously reported 
(2, 7)
. The concentration of D-GAP in 
stock solutions was determined as previously reported 
(8)
. All experiments were 
performed in duplicate. Pyruvate dehydrogeanse activity was measured 
spectrophotometrically as previously reported 
(19)
 by measuring changes in optical density 
at 340 nm. The basic assay medium (30°C), contained 100 mM HEPES (pH = 8.0), 1 
mg/mL BSA, 0.2 mM ThDP, 0.1 mM coenzyme A, 1 mM MgCl2, 2 mM cysteine, 0.3 
mM TCEP. The reaction was initiated with enzyme. Transketolase activity was measured 
as previously reported by measuring changes in optical density at 340 nm 
(20)
. The basic 
assay medium (37°) contained 50 mM glycylgylcine (pH = 7.7), 10 mM sodium arsenate, 
GADPH, 3.2 TCEP, 2.5 CaCl2, 80 μM ThDP, 70 μM xylulose-5-phosphate, 0.5 mM 
ribose-5-phosphate, 0.4 mM β-nicotinamide adenine dinucleotide phosphate sodium salt 




Inhibition Studies. Suppression of DXP synthase activity was measured 
spectrophotometrically using IspC as a coupling enzyme and monitoring NADPH 
consumption by IspC. Chemical synthesis (compounds 6-11) was carried out by Ryan 
Vierling 
(9)
. DXP synthase reaction mixtures containing 100 mM HEPES buffer, pH 8.0 
(described above) were pre-incubated at 37°C for 5 minutes with each compound. The 
reaction was initiated with enzyme. For the bisubstrate analogs that possessed 
carboxylate as a GAP mimic (compounds 1-5), inhibitory activity was evaluated using a 
range of 0 – 5 mM at 0.15 mM pyruvate and 75 µM D-GAP.  For analysis of time-
dependent inhibition by these compounds, DXP synthase was included in the reaction 
mixture and the reaction was initiated with substrates. For the acetylphosphonate studies 
the following concentrations were used to obtain Ki: compound 6 (2.5, 5, and 10 μM), 
compound 7 (10, 25, and 50 μM), compound 8 (10, 25, and 50 μM), and compound 9 
(250, 500, and 750 μM). Inhibition of DXP synthase by compounds 10 - 11 was not 
observed. Suppression of pyruvate dehydrogenase activity was measured 
spectrophotometrically by measuring changes in optical density at 340 nm. Pyruvate 
dehydrogenase reaction mixtures containing 100 mM HEPES buffer, pH 8.0 (described 
above) were pre-incubated at 30°C for 5 minutes with compound 6 (50, 100, 250 μM), 
compound 7 (50, 100, 250 μM), compound 8 (200, 500, 1000 μM). Inhibition of porcine 
pyruvate dehydrogenase by compounds 9 -11 was not observed up to 1 mM. Inhibition of 
the coupling enzyme (IspC) and transketolase from baker’s yeast by compounds 6 -11 
was not observed up to 1 mM. All experiments were performed in duplicate. Double 






General Experimental. All compound synthesis was carried out by Ryan Vierling. 
Trialkyl phosphites, acyl chlorides and lithium bromide were obtained from commercial 
sources and used without further purification.  Anhydrous acetonitrile was purchased in 
Sure-Seal bottles. All reactions were carried out in oven-dried glassware under an inert 
argon atmosphere. NMR spectra were recorded on a Bruker 400 MHz spectrometer for 
dialkyl acyl phosphonate intermediates, or a Varian 500 MHz spectrometer for final 
compounds.  Chemical shifts are reported in units of parts per million (ppm), relative to a 
standard reference point. 
1
H NMR chemical shifts are reported relative to 
tetramethylsilane (TMS,  = 0 ppm) as internal reference. 
31
P chemical shifts are reported 
relative to triphenylphosphine oxide (TPPO,  = 0 ppm) as an external standard. Mass 
spectrometry analysis was carried out at University of Illinois at Urbana-Champagne, 
School of Chemical Sciences, Mass Spectrometry Laboratory. Chemical synthesis and 
characterization of compound (6) (MAP) was reported previously 
(7)
.  Compound (9) 




Synthesis of ethyl acetyl phosphonate (7). An oven-dried flask was equipped with a 
stir-bar and charged with 0.21 mL of acetyl chloride (0.24g, 3.0 mmol). Triethyl 
phosphite (0.52 mL, 3.0 mmol) was added drop-wise at room temperature.  The solution 
was stirred at room temperature for about 1 hour, until triethyl phosphite had disappeared 
(as indicated by 
31
P NMR analysis).  Diethyl acylphosphonate was isolated as a pale 






45% yield) and was carried on without further purification. 
31
P-NMR (CDCl3):  -27.84 
(s) 
1
H-NMR (CDCl3):  1.08 (t, 6H), 2.182 (d, 3H), 4.02 (m, 4H).  
 
Diethyl acylphosphonate was dissolved in 1.7 mL of anhydrous acetonitrile. Lithium 
bromide (106.8 mg, 1.2 mmol) was added in one portion, and the reaction mixture was 
heated to 70 
o
C and stirred overnight.  The resulting white solid was filtered and washed 
with two 10 mL portions of anhydrous acetonitrile followed by two 10 mL portions of 
diethyl ether.  Ethyl acetylphosphonate (7) was isolated as a white solid (132.5 mg, 69% 
yield). 
31
P-NMR (D2O):  -27.08 (s);
 1
H-NMR (D2O): 1.17 (t, 3H), 2.34 (d, 3H), 3.84 (m, 
2H).  HRMS (ESI), calculated m/z for C4H9LiO4P (free acid form), [M+H]
+
 = 159.0399; 
observed: 159.0398.  
 
Synthesis of butyl acetylphosphonate (8). An oven-dried flask was equipped with a stir-
bar and charged with 0.40 mL of acetyl chloride (0.44g, 5.6 mmol). Tributyl phosphite 
(1.5 mL, 6.0 mmol) was added drop-wise at room temperature.  The solution was stirred 
at room temperature for about 1 hour, until tributyl phosphite had disappeared (as 
indicated by 
31
P NMR analysis).  Dibutyl acylphosphonate was isolated as a pale yellow 
oil following vacuum distillation (754mg, 90% pure as determined by 
31
P NMR, 64% 
yield) and was carried on without further purification. 
31
P-NMR (CDCl3):  -28.75 (s) 
1
H-
NMR (CDCl3):  0.94 (t, 6H), 1.42 (m, 4H), 1.71 (m, 4H), 2.49 (d, 3H), 4.16 (m, 4H).  
 
Dibutyl acylphosphonate was dissolved in 4 mL of anhydrous acetonitrile. Lithium 




heated to 70 
o
C and stirred overnight.  The resulting white solid was filtered and washed 
with two 10 mL portions of anhydrous acetonitrile followed by two 10 mL portions of 
diethyl ether.  Butyl acetylphosphonate (8) was isolated as a white solid (261.1 mg, 44%). 
31
P-NMR (D2O):  -27.01(s);
 1
H-NMR (D2O): 0.76 (t, 3H), 1.22 (m, 2H), 1.47 (m, 2H), 
2.29 (d, 3H), 3.76 (m, 2H).  HRMS (ESI), calculated m/z for C6H13LiO4P (free acid 
form), [M+H]
+
 = 187.0712; observed: 187.0709.  
 
Synthesis of methyl propionylphosphonate (9). An oven-dried flask was equipped with 
a stir-bar and charged with 0.50 mL of propionyl chloride (0.53g, 5.5 mmol). Trimethyl 
phosphite (0.60 mL, 5.1 mmol) was added drop-wise at room temperature.  The solution 
was stirred at room temperature for about 1 hour, until trimethyl phosphite had 
disappeared (as indicated by 
31
P NMR analysis).  Dimethyl propionylphosphonate was 
isolated as a pale yellow oil following vacuum distillation (542.3 mg, 98% pure as 
determined by 
31
P NMR, 64% yield) and was carried on without further purification. 
31
P-
NMR (CDCl3):  -26.77 (s) 
 
Dimethyl propionylphosphonate was dissolved in 4 mL of anhydrous acetonitrile. 
Lithium bromide (269.7 mg, 3.1 mmol) was added in one portion, and the reaction 
mixture was heated to 70 
o
C and stirred overnight.  The resulting white solid was filtered 
and washed with two 10 mL portions of anhydrous acetonitrile followed by two 10 mL 
portions of diethyl ether. Methyl propionylphosphonate (3) was isolated as a white solid 
(241.0 mg, 47%). 
31
P-NMR (D2O):  -27.01;
 1




1.47 (m, 2H), 2.29 (d, 3H), 3.76 (m, 2H).  ESI (M/S) calculated m/z for C4H9LiO4P 
(free acid form), [M+H]
+
 = 159.04 
 
Synthesis of methyl valeroylphosphonate (10). An oven-dried flask was equipped with 
a stir-bar and charged with 0.3 mL of valeroyl chloride (0.3g, 2 mmol), to which 0.3mL 
of trimethyl phosphite (0.3g, 2 mmol) was added.  After one hour, reaction mixture was 
diluted with 3.1 mL of anhydrous acetonitrile.  To this solution, 220 mg of LiBr (2.53 
mmol) was added in one portion.  The reaction mixture was warmed to 70
o
C overnight.  
The solid white precipitate was filtered with two 10 mL portions of anhydrous 
acetonitrile, followed by two 10 mL portions of diethyl ether.  Methyl 
valeroylphosphonate was isolated as a white solid (110.3mg, 23% overall yield).   
31
P-
NMR (D2O):  -25.89 (s);
 1
H-NMR (D2O): 0.79 (t, 3H), 1.18 (m, 2H), 1.46 (m, 2H), 2.73 
(t, 2H), 3.52 (d, 3H).  HRMS (ESI), calculated m/z for C6H13LiO4P (free acid form), 
[M+H]
+
 = 187.0712; observed: 187.0708.  
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Chapter 4: Antimicrobial activity of butylacetylphosphonate. 
 
Introduction 
In many bacterial pathogens, DXP synthase is a branch point in metabolism; DXP 
is a precursor to pyridoxal phosphate (PLP) biosynthesis and, interestingly, also a 
precursor to its own essential cofactor, thiamin diphosphate 
(1-3)
 (for additional 
information, see section 1.4. Despite its importance in bacterial metabolism, DXP 
synthase is underdeveloped as a drug target. Ostensibly, this is largely due to perceived 
challenges in achieving selective inhibition of DXP synthase over mammalian ThDP-
dependent enzymes, such as the E1 subunit of pyruvate dehydrogenase (E1 PDH) and 
transketolase (TK), and few reports describe inhibitors of this enzyme 
(4-7)
. However, 
DXP synthase appears unique amongst ThDP-dependent enzymes (for additional 
information, see Chapter 2) 
(6-9)
. Indeed, we have demonstrated that selective inhibition of 
E. coli DXP synthase is achievable with unnatural bisubstrate analogs including 
butylacetylphosphonate (BAP) 
(10)
 and benzylacetylphosphonate (BnAP) 
(8)
, both bearing 
an acetylphosphonate mimic of pyruvate 
(11-13)
  and a sterically demanding unnatural 
acceptor substrate (for additional information, see Chapter 3). Presumably, sterically 
demanding acetylphosphonates bind in the large DXP synthase active site and react with 
bound ThDP, in a manner similar to methylacetylphosphonate 
(14-18)
, to form a stable 
phosphonolactyl-thiamin diphosphate (PLThDP) intermediate, effectively trapping the 
enzyme at a pre-decarboxylation complex (Figure 4-1).   
In this chapter, we describe studies to evaluate the antimicrobial activity of BAP 




Koppisch, Northern Arizona University). Our results indicate that BAP possesses modest 
antibacterial activity via a mechanism that appears to involve inhibition of DXP synthase, 
and drug synergism is evident with BAP-fosmidomycin combinations in E. coli. These 
results suggest that selective inhibitors of DXP synthase could be effective in antibiotic 
combinations. 
 







4.1. BAP exhibits weak antimicrobial activity. As a starting point, BAP was evaluated 
for antimicrobial activity against the Escherichia coli ATCC strain MG 1655 using the 
macrodilution method 
(20, 21)
. BAP exhibits minimum inhibitory concentrations (MIC = 
[BAP] causing growth inhibition) of ~1 000 µg/mL in cation-adjusted Mueller Hinton 
Broth (Table 4-1) and a significantly lower MIC of 122 µg/mL in M9 minimal media. 
BAP was evaluated against several clinically isolated pathogens (Dr. Andrew Koppisch, 
Table 4-1), and BAP exhibits an MIC of 4 000 µg/mL against Salmonella enterica 
serovar Typhimurium and Micrococcus sp., 1 000 µg/mL against Bacillus anthracis 
Sterne, and 4 000 µg/mL against Pseudomonas aeruginosa in cation adjusted Mueller 





organism MIC (µg/mL) 
Bacillus anthracis Sterne 
1 
1000 
Bacillus subtillis  > 2000 
Bacillus thuringiensis HD34 
1 
> 4000 
Enterobacter cloacae > 4000 
Escherichia coli 1000 
Klebsiella oxytoca > 4000 
Klebsiella pneumonia > 4000 
Micrococcus sp. 2000 
Mycobacterium smegmatis  > 2000 
Pseudomonas aeruginosa 4000 




Salmonella typhimurium 4000 
Staphylococcus aureus
2
 > 4000 
 




 Fractional growth was determined as 
outlined in the Experimental Section, but with slightly longer incubations (22-24 hrs) at 
37 °C. 
2
 Does not use the MEP pathway. 
 
We considered the possibility that the weak antimicrobial activity of BAP is 
attributed to poor cellular uptake. Small phosphorylated (or phosphonylated) molecules, 
including the phosphonate fosmidomycin, are actively transported via the glycerol 3-
phosphate transporter (glpT) 
(22-24)
. BAP was evaluated for antimicrobial activity against a 
glpT knockout strain (JW2234-2) and its parent strain (BW25513) (Yale, Coli Genetic 
Stock Center) to determine whether this is a possible uptake mechanism. However, while 
fosmidomcyin is inactive against the glpT knockout strain, BAP exhibits comparable 
antimicrobial activity against the glpT knockout and parent strains (Figure 4-2). This 








Figure 4-2.  BAP and fosmidomycin (FOS) antimicrobial activity against glycerol 3-
phosphate transporter knockout (glpT-). A) BAP evaluated for antimicrobial activity 
against a glpT knockout strain (JW2234-2) and its parent strain (BW25513) (Yale, Coli 
Genetic Stock Center). Fractional growth was determined with increasing BAP: 0 mM 
(blue), 0.16 mM (red), 0.33 mM (green), 1.31 mM (purple), 2.63 mM (teal), 5.25 mM 
(orange). B) Fractional growth was determined with increasing fosmidomycin: 0 mM 
(blue), 3 µM (red), 6 µM (green), 12.5 µM (purple), 25 µM (teal), 50 µM (orange). 




susceptibility studies). The mean and standard deviation of two biological replicates is 
shown. 
 
4.2. DXP synthase is an intracellular target of BAP. Experiments to rescue the growth 
inhibitory effects of BAP against E. coli MG1655 were performed to provide evidence 
for DXP synthase as an intracellular target. 
 
4.2.1. Rescue by downstream metabolites.  
Previous reports demonstrate labeling of downstream MEP pathway intermediates 
in E. coli in feeding experiments using labeled 1-deoxy-D-xylulose (DX), suggesting DX 
is cell permeable and undergoes intracellular phosphorylation at some level to produce 
DXP 
(25, 26)
. Here, partial rescue of BAP inhibitory activity is observed when the growth 
medium is supplemented with DX (50% reduction in growth inhibition by BAP in the 
presence of DX) (Figure 4-3A). As DXP synthase is a branch point in bacterial 
metabolism, additional biosynthetic pathways including thiamin diphosphate and 
pyridoxal phosphate biosynthesis 
(1-3)
 should be affected by inhibition of DXP synthase. 
Further, inhibition of ThDP biosynthesis might potentiate the loss of DXP synthase 
activity as this cofactor is also required for DXP synthase-catalysis. Complete rescue of 
growth inhibitory effects of 31.25 µg/mL BAP (165 µM) is observed in the presence of 
thiamin (Figure 4-3B). E. coli growth rates in the presence or absence of thiamin are 
similar (Figure 4-3C), suggesting intracellular thiamin concentration is sufficient to 
support normal growth under conditions where ThDP biosynthesis is not inhibited. Cells 




treated cells is restored by 16 hours in the presence of thiamin, there is a clear delay in 
growth under these conditions. This may reflect the time required for intracellular 
phosphorylation of thiamin under growth inhibitory conditions. Under conditions of 








Figure 4-3. Butylacetylphosphonate (BAP) inhibition of E. coli MG1655 growth is 
rescued by 1-deoxy-D-xylulose (DX), thiamin (Th) and E. coli DXP synthase (Dxs) 




and DX. Mean and standard error of four replicates are shown. 
*
p = 0.022 (unpaired t test 
comparing DX treated and untreated cultures at 0.66 mM BAP). B) Fractional growth at 
16 hours in the presence and absence of BAP and thiamin. Mean and standard error of 
four replicates is shown. 
***
p = 0.0000258 (unpaired t test comparing thiamin treated and 
untreated cultures at 165 µM BAP). C) Growth curve over 16 hours, in the absence or 
presence of BAP and thiamin. D) Fractional growth at 16 hours determined for E. coli 
BL21 cells only, cells transformed with empty pET37b vector, vector expressing 
recombinant E. coli DXP synthase protein (dxs-pET37b), or vector expressing the 
catalytically inactive 
(9)
 E370A variant (E370A dxs-pET37b). Mean and standard error of 
four replicates is shown. 
 
4.2.2. Metabolites that failed to rescue growth.  
In addition to DX, a number of additional downstream metabolites were 
supplemented to cell culture media in attempt to rescue growth. A wide range of 
metabolite concentrations were examined at a variety of different BAP concentrations, 
under different assay conditions (Table 4-2). None of these intermediates were able to 
rescue the growth inhibitory effects caused by BAP and there are several explanation for 
this. It is possible that under these experimental conditions there is inefficient turnover of 
the metabolite or insufficient uptake by the cell.  Furthermore, studies involving rescue 
by metabolites in the isoprenoid pathway 
(5, 27-30)






Table 4-2. Metabolites that failed to rescue growth of E. coli treated with 
butylacetylphosphonate (BAP). 
 
4.2.3. Rescue by overexpression of E. coli DXP synthase.  
Overexpression of DXP synthase should rescue growth of BAP-treated E. coli 
(31)
 
if BAP acts by inhibition of DXP synthase. Indeed, increasing intracellular levels of DXP 
synthase results in rescue of bacterial growth (Figure 4-3D) compared to E. coli 
harboring empty vector (pET37b) or the catalytically inactive E370A mutant 
(9)
. It should 
be noted that the T7 promoter, a lac promoter that is used in the pET plasmid systems, is 
known for background expression of recombinant protein. Under the conditions used 
here, the E. coli dxs-pET37b plasmid is capable of expressing DXP synthase in the 
absence of inducer, such as IPTG (Figure 4-4) and this basal expression is sufficient to 








Figure 4-4.  DXP synthase overexpression confirmed by 10% SDS-PAGE. 
Standardized inoculum was prepared as described in Material and Methods (see 
Antimicrobial susceptibility studies), and 5 mL cultures were analyzed after 16 hours in 
the absence of inducer. 1) protein marker (2-212 kDa) 2) E. coli BL21 cells only 3) cells 
transformed with empty pET37b vector 4) vector expressing recombinant E. coli DXP 
synthase protein (dxs-pET37b) 5) vector expressing the catalytically inactive E370A 
(9)
 
variant (E370A dxs-pET37b). A) Visualization by coomassie stain B) Incorporation of 
the histidine tag was verified using the InVision His-tag In-gel Stain (Invitrogen). The red 
arrow denotes recombinant E. coli DXP synthase. 
 
To allow expression to be dependent upon inducer concentration, this background 
expression of DXP synthase would need to be silenced. In attempt to silence this 
background expression, and show a clear dose response relationship between increasing 




modifications to this method were explored. It has been reported that addition of glucose 
to cell culture media will silence basal expression, a phenomenon known as catabolite 
repression. In the presence of glucose, cyclic AMP levels decrease and this should result 
in very low levels of transcription from the lac promoter. However, addition of 0.5 – 5 % 
glucose to cell culture media did not eliminate basal expression of E. coli DXP synthase. 
Additionally, cells containing T7 lysozyme (BL21 (DE3) pLysS, Promega) were used in 
attempt to silence this basal expression of DXP synthase. T7 lysozyme is a natural 
inhibitor of T7 RNA polymerase and lowers the basal expression level of genes under the 
control of the T7 promoter, but does not interfere with the level of expression achieved 
following induction by IPTG. In this cell line, basal expression was silenced and 
expression of DXP synthase became strictly inducible. However, rescue of growth 
inhibition by BAP was not observed when DXP synthase expression was induced with 
IPTG.  
It is possible that under the growth inhibition conditions used for these studies, 
introduction of IPTG and subsequent initiation of protein overproduction machinery in 
the cell is a cause of toxicity. As a control, BL21 cells alone, BL21 cells transformed 
with pET37b, and BL21 cells transformed with dxs-pET37b were treated with and 
without IPTG under the growth inhibition conditions. IPTG had no effect on BL21 cells 
alone, while there was a 70% decrease in optical density (OD600) for cells transformed 
with the pET37b plasmid and exposed to IPTG. This toxicity was even more pronounced 
for the BL21 cells harboring dxs-pET37b; we observed an 89% drop in optical density. 
These results are in agreement with previous studies that show overexpression plasmids 






4.3. Growth inhibition is significantly enhanced when BAP is administered in 
antibiotic combinations.  
The weak antimicrobial activity of BAP on its own prompted a study to determine 
the synergistic effects of BAP in combination with several established antibiotics. As a 
starting point, we investigated synergistic effects of BAP in combination with 
fosmidomycin, ampicillin, and tetracycline using the checkerboard method 
(20, 21)
. 
Fosmidomycin potently inhibits the second enzyme in the MEP pathway, MEP synthase 
(IspC) 
(33-35)
. Given the established synergy that can take place between agents that target 
the same metabolic pathway, and in particular the synergy observed between 
fosmidomycin and inhibitors of isoprenoid biosynthesis enzyme farnesylpyrophosphate 
synthase (FPPS) 
(36)
, we hypothesized that BAP could synergize with fosmidomycin. 
Likewise, fosmidomycin has been shown to synergize with cell wall biosynthesis 
inhibitors, including ampicillin, to inhibit bacterial cell growth 
(37)
. Those early 
observations established precedence for drug synergisms between agents targeting 
isoprenoid biosynthesis and cell wall biosynthesis (which relies upon the prenylated 
Lipid II) and suggest synergy between BAP and cell wall biosynthesis inhibitors is also 
possible. Finally, we considered the possibility that synergy could exist between BAP and 
the bacterial translation inhibitor tetracycline, on the basis that geranylation of tRNA is 
proposed to play a role to modulate codon recognition during translation 
(38)
, thus 







organism MIC BAP  (µg/mL) combination  FIC index 





Table 4-3. Antimicrobial activity of BAP against pathogenic bacteria and FIC index 




Here, the fractional inhibitory concentration (FIC) index was determined for 
BAP-fosmidomycin, BAP-ampicillin, and BAP-tetracycline combinations against E. coli 
MG1655 to predict drug synergisms 
(20, 21, 39)
. As expected, the antimicrobial activity of 
BAP is enhanced in combination with fosmidomycin (FIC index = 0.25, Table 4-3) or 
ampicillin (FIC index = 0.31, Table 4-3). Analysis by isobolograms suggests pronounced 
synergy in the BAP-fosmidomycin combination against E. coli MG1655 (Figure 4-5) 
(19, 
20, 38)
. However, examination of the BAP-ampicillin combination by isobologram 
indicates synergy is less pronounced, suggesting this combination may display additive 
effects. The FIC index for BAP in combination with tetracycline is 0.53, indicating an 












Figure 4-5. Checkerboard antibiotic combination studies 
(19)
. A) Heat plots showing 
drug synergism for BAP-fosmidomycin and BAP-ampicillin, and additivity for BAP- 
tetracycline. B) Isobologram analysis suggests synergy in the BAP-fosmidomycin 









As the isoprenoid biosynthetic pathway is absent in mammals, but essential in 
many human pathogens, each of the seven enzymes in the pathway represents a 
prospective antibiotic target. Selective inhibition of DXP synthase could reduce flux 
through multiple metabolic pathways and is a potential advantage of targeting this first 
step of the MEP pathway. Here we have evaluated the inhibition and antimicrobial 
activity of butylacetylphosphonate (BAP), a DXP synthase inhibitor developed in our lab 
to selectively target the uniquely large active site of this enzyme 
(10)
. 
BAP appears to exert antimicrobial activity against E. coli MG1655 through a 
mechanism that involves DXP synthase inhibition, as suggested by the observed rescue 
of its inhibitory effects in the presence of DX or thiamin, or under conditions of DXP 
synthase overexpression. Partial rescue is observed using nonphosphorylated 1-deoxy-D-
xylulose (DX), implying DXP synthase as a target. More pronounced rescue is observed 
in the presence of thiamin or DXP synthase overexpression. In addition to rescuing the 
thiamin pathway and other thiamin-dependent cellular processes under these conditions, 
it is possible that ThDP generated under thiamin rescue conditions regenerates active DX 
synthase by competing with butylphosphonolactyl-thiamin disphosphate (butyl PLThDP) 
at the ThDP binding site. Alternatively, increasing intracellular ThDP levels could 
activate an apo-DXP synthase pool that presumably arises under conditions of DXP 
synthase inhibition and subsequent cofactor depletion. Not surprisingly, overexpression 
of active DXP synthase in E. coli also results in pronounced rescue of BAP growth 




conditions with increasing BAP is consistent with DXP synthase inhibition coupled with 
other nonspecific antimicrobial effects of BAP at high concentrations.  
The reason for the observed weak antimicrobial activity of BAP on its own 
against the pathogens tested here is not entirely clear, although poor cell permeability is 
conceivable. Recent studies by Circello, et al. 
(40)
 reveal the natural product dehydrophos 
as a prodrug of the structurally related methyl acetylphosphonates (MAP), a mimic of 
pyruvate and known inhibitor of the ThDP-dependent enzymes that catalyze 
decarboxylation of pyruvate (see 1.9 for additional information) 
(14-18)
. By extension, the 
acetylphosphonate scaffold of BAP may hamper efficient uptake in the absence of such a 
delivery mechanism. It is intriguing to contemplate a similar delivery strategy for 
enhancing cellular uptake of BAP and analogs, although it is also possible that 
incorporation of more hydrophobic substituents may enhance permeability. 
Despite the weak antimicrobial effects of BAP on its own, a BAP-fosmidomycin 
combination is synergistic against E. coli MG1655. The synergistic BAP-fosmidomycin 
combination was anticipated, given that drug synergism in the MEP pathway has been 
previously reported with FPPS inhibitors and fosmidomycin 
(36)
. Our previous work 
suggesting MEP activates and sustains IspF activity in a possible feed-forward regulatory 
mechanism in bacterial isoprenoid biosynthesis 
(41)
 could provide additional basis for this 
synergistic combination. It is conceivable that inhibition of upstream enzymes DXP 
synthase and IspC by BAP and fosmidomycin, respectively, not only reduces flux 
through the pathway at these points, but also effectively expedites the loss of IspF 
activity by rapidly depleting MEP levels. There is established precedence for drug 






given the requirement for isoprenoid precursors in Lipid II biosynthesis 
(31)
, and so the 
enhancement in activity observed with the BAP-ampicillin combination in this study was 
also anticipated. It is also plausible that ampicillin compromises cell wall integrity to 
permit more efficient uptake of BAP. These findings are significant given the necessity of 
combination therapies to prevent emergence of antimicrobial resistance 
(42)
. Although 
inhibition of DXP synthase ought to simultaneously reduce flux through multiple 
essential pathways, the emergence of mechanisms to circumvent such an intervention in 
bacteria is inevitable 
(42-44)
.  
This work highlights unnatural bisubstrate analogs as selective inhibitors of this 
unique ThDP-dependent enzyme and promising antimicrobial agents as components of 
synergistic antimicrobial combinations. While the acetylphosphonates were developed 
over 30 years ago as ketoacid mimics, and are powerful tools to study ThDP-dependent 
enzymes 
(14-18)
, in the case of dehydrophos, it is clear that Nature has already conceived 
of such an antimicrobial strategy to inhibit essential ThDP-dependent processes. 
Development of acetylphosphonates to increase selectivity, potency, and permeability is 













General Methods. Primers were purchased from Integrated DNA Technologies. E. coli 
wild-type DXP synthase and the variant E370A DXP synthase were purified as described 
previously 
(7, 45)
.  E. coli MEP synthase (IspC) was also purified as reported previously 
(45)
. All microbial manipulation of pathogenic bacteria was conducted in a certified 
biosafety level 2 (BSL-2) laboratory with all associated safety protocols. S. enterica 
serovar Typhimurium LT2, B. anthracis Sterne, and all clinically isolated strains are 
maintained from an in-house bacterial strain library (NAU). 
 
Antimicrobial susceptibility studies. Using aseptic technique, three to five isolated 
colonies were picked from a plate containing ATCC MG1655 E coli and Bacillus subtilis 
168 were inoculated into 5 mL of cation adjusted Mueller Hinton Broth (CAMHB, 
Sigma) at 37°C. Incubation was continued until turbidity matched McFarland (MF) 
turbidity standard 0.5 (~OD600 = 0.10) 
(20, 21)
. Colony counts were checked after 16 hours 
at 37°C for consistency between experiments. The standardized inoculums (MF = 0.5) 
contained approximately 1–2 x 10
8
 CFU/mL. The final concentration in a well (or culture 




. For these studies, the standardized inoculum (MF = 
0.5) was diluted 1:100 in CAMHB and 0.25 mL of this adjusted inoculum was added to 
each tube containing 0.25 mL antimicrobial agent(s) for a final volume of 0.5 mL. These 
tubes were then incubated at 37°C for 16–18 hours, with shaking. Fractional growth was 
determined relative to the no drug control, and averaged values were used. The minimum 




was ≤ 15% of the no drug growth controls (determined by OD600) 
(20, 21, 39)
. The 
concentration of BAP evaluated for these studies ranged from 0 - 5 mM (0 - 1 000 
µg/mL). ATCC 70084 Mycobacterium smegmatis was evaluated in a similar manner 
outlined above, but using enriched Middlebrook 7H9 broth. A 24 hour culture (~ OD600 = 
0.4) was diluted to OD600 = 0.1 and subcultured 1:100 for 1 x 10
6 
colony forming units. 
The concentration of BAP was varied 0  10 mM (0 - 2 000 µg/mL). The E. coli glycerol 
3-phosphate transporter knockout strain (JW2234-2) was evaluated along with the parent 
strain (BW25113) using the above method (Yale, Coli Genetic Stock Center, CGSC). 
Susceptibility studies were performed for S. enterica serovar Typhimurium LT2, B. 
anthracis Sterne, and all clinical isolates essentially as outlined above with the exception 
that the assays were conducted in 96-well plates with final volume of 0.2 mL, and 
concentrations of BAP ranged from 0 - 20 mM (0 – 4 000 µg/mL). All antimicrobial 
susceptibility assays were performed in triplicate. 
 
E. coli growth rescue studies. For the growth rescue experiments, 96-well plates were 
used with a final culture volume of 0.2 mL. The standardized inoculum (MF = 0.5) was 
prepared in the same manner as previously stated. These plates were then incubated in a 
SpectramaxPlus384 plate reader at 37°C for 16 hours, with shaking at 220 rpm every 30 
minutes for 15 minutes.  Less than 10% loss in volume was measured during this time. 
Fractional growth was then determined relative to the no BAP control in each case, and 
averaged fractional growth was plotted with standard experimental error as a function of 
BAP concentration. For the 1-deoxy-D-xylulose (DX) rescue experiments, a range of 0 - 




the thiamin rescue experiments, a range of 0 - 1.0 mM thiamin was evaluated in the 
presence of 0 - 0.66 mM BAP in M9 minimal media (no thiamin). DX and thiamin rescue 
experiments were performed in quadruplicate. DXP synthase overexpression rescue 
experiments were carried out in LB broth, and the following cell types were treated with 
0-5.0 mM BAP: BL21 (no vector), pET37b-BL21, wt E. coli dxs-pET37b/BL21, and 
E370A E. coli dxs-pET37b/BL21. Experiments were performed in triplicate.  
DXP synthase overexpression was confirmed by 10% SDS-PAGE, and 
incorporation of the octa-histidine tag was verified using the InVision His-tag In-gel Stain 
(Invitrogen) (Figure S2). Site directed mutagenesis of the E370A residue was carried out 
as previously reported 
(7)
 using the QuikChange sitedirected mutagenesis kit (Stratagene), 
and the following primers (Integrated DNA technologies):  5’ CGA CGT GGC AAT 
TGC CGC GCA ACA GCG GGT GAC CTT TGC 3’ and 5’ GCA AAG GTC ACC 
GCG TGT TGC GCG GCA ATT GCC ACG TCG 3’. 
 
Checkerboard antibiotic combination studies. For the checkerboard antibiotic 
combination studies in E. coli, culture tubes were used with a final culture volume of 0.5 
mL, prepared as described above.  The concentration of ampicillin evaluated for these 
studies ranged from 0, 0.13, up to 8 µg/mL, tetracycline ranged from 0, 0.125, up to 4 
µg/mL, and fosmidomycin ranged from 0, 0.19, up to 6 µg/mL.  
For each antibiotic combination, the fractional inhibitory concentration (FIC) 
index was determined to predict drug synergism 
(20, 21, 39)
.  
     
        
  
   
      




The FIC index was calculated using equation 1 
(20, 21, 39)
. MICBAP and MICX are the lowest 
concentrations of BAP or drug X (X = ampicillin, fosmidomycin, or tetracycline) 
showing < 15% growth. The FICBAP was calculated as the [BAP in the presence of drug 
X] for a well showing < 15% growth, divided by MICBAP. FICX was calculated as the 
[drug X in the presence of BAP] in the same well, divided by MICX. The FIC index is the 
sum of FICBAP and FICX. For each combination the FICI values were used to indicate 
drug synergism (x < 0.5), additivity (0.5 < x < 1.0), indifference (1.0 < x < 2.0), or 
antagonism (x > 2). Fractional growth was determined relative to the no drug growth 
control and average values were used. The BAP-ampicillin and BAP-tetracycline 
checkerboard assays were performed in duplicate. The BAP-fosmidomycin checkerboard 
assay was performed in quadruplicate.  
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Chapter 5: Targeting DXP reductoisomerase (IspC) using fosmidomycin analogs. 
 
Introduction 
 DXP reductoisomerase (IspC) is the second enzyme in the MEP pathway, and 
catalyzes the first committed step in non-mammalian isoprenoid biosynthesis to form 2C-
methyl- D -erythritol 4-phosphate (MEP). IspC catalyzes the reduction and rearrangement 
of DXP to generate MEP in a magnesium and NAPDH dependent manner 
(1)
. The first 
step of the reaction gives the branched aldose derivative, 2C-methyl- D -erythrose 4-




Figure 5-1. Reaction catalyzed by DXP reductoisomerase (IspC). 
 
Fosmidomycin (1) is a potent inhibitor of IspC (Km
DXP
 = 115 µM; Ki
fosmidomycin
 = 
57 nM for Synechocystis sp. PCC6803 IspC) 
(2, 3)
 and the most potent inhibitor of 
isoprenoid biosynthesis in human pathogens utilizing the MEP pathway. Currently, 
fosmidomycin is in phase 3 clinical trials for the treatment of uncomplicated malaria in 
combination with clindamycin (see section 1.4) 
(4, 5)
. Crystallography studies report that 




induces a conformation change that closes a flexible loop over the active site 
(6)
. Three 
regions in the active site have been identified that accommodate the hydroxamate, carbon 
linker, and phosphonate moiety of fosmidomycin. As discussed in 1.13, several structure 
activity relationship (SAR) studies have been carried out around this inhibitor (Figure 1-
13) 
(2, 7-11)
 in efforts to address the poor pharmacokinetic properties of this phosphonyl-
bearing inhibitor. Analogs of fosmidomycin include fosfoxacin and its N-acetyl congener 
(FR900098). Although these compounds are potent in vitro inhibitors of purified IspC, 










In order to improve the efficacy and bioavailability of fosmidomycin and its 
analogs, new tactics are required. Several strategies have been pursued to address 
pharmacokinetic issues. Alpha-substituted lipophilic analogs increase permeability, but 
these compounds are less potent inhibitors of purified IspC 
(11)
. In a different approach, 
researchers sought to improve pharmacokinetic properties by masking the phosphonate 
moiety of FR900098 as a phosphodiarylester 
(10)






These compounds were expected to be cell permeable and activated intracellularly via 
enzyme-catalyzed hydrolysis by non-specific plasma phosphatases or esterases, 
respectively 
(9, 10, 13)
. Although one diarylester prodrug (Figure 5-2, compound 1) 
demonstrated efficacy in mice infected with the rodent malaria parasite Plasmodium 
vinckei, concerns were raised about toxicity of the phenol derivative released through P-
O cleavage of this prodrug class. The alkoxycarbonyloxyethyl ester prodrugs (Figure 5-
2, compound 2) displayed two-fold higher activity in a parasitic mouse model compared 
to FR900098, and a higher plasma concentration was measured after oral administration. 
Yet there are concerns regarding premature prodrug activation outside of the cell which 
creates membrane impermeable, toxic precursors. Another drawback of these masked 
FR900098 analogs includes the inefficient chemistry of activation. Two enzymatic 
activation events catalyzed by phosphatases or esterases are required to unmask these 
analogs, and the second of these events is often especially slow.  
In this chapter, we present two approaches to combat the pharmacokinetic issues 
associated with fosmidomycin and fosfoxacin and their N-acetyl derivatives. The first 
approach takes advantage of the “two part” substrate hypothesis which has been 
previously reported 
(14, 15)
.  Taking triosephosphate isomerase (TIM) an example, it was 
proposed that the intrinsic binding energy of a phosphodianion group of the substrate is 
what drives the closing of a mobile loop and results in a protein conformational change 
(15)
. More recently, this strategy has been used to investigate the role of the nonreacting 
phosphoryl group in the IspC-catalyzed formation of MEP from DXP 
(16)
. The reaction of 
the truncated 1-deoxy-L-erythrulose (DE) substrate was monitored in the presence and 
absence of phosphite dianion. Kholodar et al 
(16)




takes place upon substrate binding to IspC, and is driven by binding of the dianionic 
phosphoryl group. Likewise, binding of fosmidomycin induces a phosphonyl-dependent 
conformational change during inhibition. We have tested the hypothesis that membrane 
permeable, truncated fosmidomycin analogs lacking the dianionic phosphonyl group can 
be designed to inhibit IspC in a “two part” inhibitor mechanism. These analogs can be 
used in combination with intracellular anions that will facilitate analog binding and 
conformational changes (Figure 5-3A). The truncated N-hydroxyethyl fosfoxacin analog 
was designed to either act in a “two part” inhibitor mechanisms or undergo intracellular 






Figure 5-3. Truncated FR900098/fosfoxacin analogs target IspC. A) Binding of 
fosmidomycin induces a conformation change to close a flexible loop over the active site 
of IspC (“closed conformation”) 
(6)
. Binding of truncated analogs (3-6) in combination 
with intracellular anions is proposed to similarly induce the closure of the active site of 
IspC leading to inhibition of the enzyme. Pi : inorganic phosphate. B) Activation by 





In a distinct approach, we sought to mask the charges of the phosphonyl group by 
developing a phosphonamidate-based prodrug (7) requiring a single, efficient 
bioactivation event, rather than two bioactivation events. The prodrug is designed to 
incorporate a bioreducible delivery group susceptible to activation by intracellular 
reductases, and does not require activation by esterases or phosphatases which are also 
extracellular. After cellular uptake, bioreduction will result in the formation of the 
corresponding electron rich hydroxylamine, which rapidly undergoes elimination to 
release a phosphonamidate anion  (Figure 5-4). Similar amidate-based prodrug strategies 
have been successfully implemented in previous studies for the intracellular delivery of 
nucleotide monophosphates 
(17-20)















5.1. Biochemical evaluation of truncated FR900098 analogs. 
Prior to evaluating the inhibitory activity of FR900098 analogs, E. coli IspC was 
kinetically characterized with respect to its natural substrates (Km 
DXP
 = 150 ± 9 µM, Km 
NADPH
 = 4 ± 0.5 µM, kcat = 9.3 ± 2.7 min
-1
, Figure 5-5). The kinetic parameters for E. coli 
IspC with respect to NAPDH and DXP are comparable to those previously reported 
(2)
.   
 
Figure 5-5. Kinetic characterization of E. coli IspC. A) DXP concentration was varied 
at 0.1 mM fixed NAPDH. B) NADPH concentration was varied at 0.5 mM fixed DXP. 
 
As a starting point to test the “two part” inhibitor hypothesis, IspC activity was 
then examined in the presence of a variety of common intracellular anions that could 
potentially bind in the active site phosphonyl binding pocket and presumably act together 
with truncated FR900098 or N-acetyl fosfoxacin analogs to inhibit IspC. Anions selected 
for these studies included: chloride (intracellular concentration = 5 - 15 mM), bicarbonate 
(intracellular concentration = 12 mM), inorganic phosphate and diphosphate (intracellular 
concentration ~ 0.8 - 100 mM, although subject to debate due to difficulty measuring) 
(22, 
23)




diphosphate inhibit the enzyme (Figure 5-6). This was expected, as there is a well-
defined phosphoryl binding pocket within the active site of IspC 
(6)
. The enzyme was also 
inhibited 46% in the presence of 10 mM chloride. 
 
Figure 5-6. Activity of IspC in the presence of phosphate, chloride, bicarbonate, and 
diphosphate.  
 
Truncated analogs (3-6, synthesized by Dr. David Meyers, Synthetic Core 
Facility) were then evaluated as inhibitors of IspC, and showed no inhibitory activity up 
to 10 mM. Following these experiments, truncated analogs (3-6) were then evaluated in 
combination with the previously tested anions. The inhibitory activity of compounds 4 - 6 
is not enhanced in the presence of anions (Figure 5-7), although there is a slight decrease 
in the rate when compound 5 is combined with 0.25 µM diphosphate (Figure 5-7D). At 






Figure 5-7. Evaluation of truncated FR900098 analogs 4 - 6 in combination with 
anions. Concentration of analog were varied from 0-5 mM. Activity assays were carried 
out in: A) 5 mM sodium chloride (NaCl), B) 5 mM bicarbonate, C) 5 mM inorganic 
phosphate, and D) 0.25 µM diphosphate.  
 
 The inhibitory activity of compound 3 is enhanced in the presence of inorganic 
phosphate (Figure 5-8). Further analysis indicates that enhanced inhibitory activity of 3 
in the presence of inorganic phosphate is mutually dependent (using the Yonetani 
Theorell equation, Equation 1) 
(24)
. 
    
  
    
     
     
     
     
     
 
   
   
  
        
         
   
     Equation 1 
Where vi = rate, Vm = maximum rate, and α = the interaction constant between AHA and 
phosphate in the E-AHA-phosphate complex. It is assumed that inhibitors and substrates 






. For this analysis, terms were grouped into phenomenological variables to 
allow convergence. The Yonetani Theorell plot is shown in Figure 5-8. When α = 0, two 
competitive inhibitors compete for the same site, and lines on the corresponding Yonetani 
Theorell plot will have parallel slopes. When  > α > 0, two competitive inhibitors are 
interacting at different regions of a binding site in a mutually dependent relationship, and 
both the slope and intercept of the plots of 1/vi versus AHA concentration will increase as 
linear functions of phosphate. A mutually dependent relationship is observed for AHA 
and phosphate, indicating they bind in different regions of the substrate binding site. 
 
 
Figure 5-8. Inhibition of E. coli IspC by acetohydroxamic acid (AHA) is enhanced in 









5.2. Confirming the reductive activation of FR900098 phosphonamidate prodrug. 
Prodrug 7 (also synthesized by Dr. David Meyers, Synthetic Core Facility) was 
evaluated against IspC for inhibitory activity, and as expected, no inhibition was 
observed up to 0.5 mM prodrug. This was anticipated, as this prodrug is not activated to 
facilitate release of the IspC inhibitor FR900098 under standard IspC assay conditions. 
Inhibition of IspC under reducing conditions is more biologically relevant. Intracellular 
nitroreductases are known to reduce nitrogroups on diverse classes of substrates 
(25)
; thus, 
these experiments were repeated following incubation of prodrug 7 with E. coli 
nitroreductase. The nitroreduction reaction was monitored at 340 nm to measure the 
disappearance of NADH. Under the conditions used here (see Experimental Section), the 
nitroreductase reaction was complete within 5 minutes. However, elimination, 
cyclization, and P-N hydrolysis events are also required to fully unmask compound 7 
(Figure 5-4); thus, the incubation period was extended to 6 hours to ensure some amount 
of prodrug activation and FR900098 release. In these preliminary experiments, the 
apparent IC50 value for prodrug 7 post incubation is comparable to the IC50 values for 
fosmidomycin and FR900098 (IC50
fosmidomycin 
= 240 ± 80 nM; IC50
FR900098 
= 59 ± 2.1 nM ; 
IC50 
apparent, prodrug 7 
= 270 ± 90 nM) (Figure 5-9). This preliminary result, combined with 
the observation that prodrug 7 is not an inhibitor of IspC in the absence of nitroreductase, 






Figure 5-9. Apparent IC50 values for A) Unmasked FR900098 phosphonamidate 
prodrug, B) FR900098, and C) fosmidomycin. Experiments were performed in 
duplicate with representative plots shown. 
 
5.3. Truncated FR900098 analogs evaluated against Plasmodium falciparum. 
Compounds 3 - 7 were evaluated against P. falciparum (NF54), in collaboration 
with Prof. Theresa Shapiro, Johns Hopkins University, Dept. Pharmacology and 
Molecular Sciences (Table 5-1). Interestingly, prodrug 7 exhibits a comparable EC50 
value to fosmidomycin (EC50
FR900098
 = 0.93 µM; EC50
7
= 1.03 µM). This suggests that 
after cellular uptake, the prodrug is capable of activation and subsequently inhibition of 
IspC. The EC50
 
of truncated analog 6 is ~27-fold higher than fosmidomycin, suggesting 
this membrane permeable analog can undergo phosphorylation to generate fosfoxacin, 
and then inhibit IspC. Compounds 3 and 4 also exhibited weak anti-parasitic activity with 








compound EC50 (µM) 
fosmidomycin 
+








 25 ± 0 
7 
+
 1.03 ± 0.07 
 
Table 5-1. Anti-parasitic activity of fosmidomycin/FR900098 truncated analogs 




performed in medium supplemented with Albumax II. 
 
It has been previously shown that fosmidomycin inhibition of P. falciparum can 
be chemically rescued by supplementation with isopentenyl diphosphate (IDP) 
(26)
. This 
finding suggests an essential role of isoprenoids in parasites, and provides a valuable tool 
for validation of MEP pathway inhibitors. To validate the MEP pathway as the target of 
compounds 6 and 7, and reduction of flux through the MEP pathway as the cause of anti-
parasitic activity, rescue of anti-parasitic activity using isopentenyl diphosphate (IDP) 
was carried out (Figure 5-10).  Parasite survival was observed for compounds 6 and 7 in 
the presence of IDP, as well as the fosmidomycin and FR900098 controls. Preliminary 
experiments to assess the antibacterial activity of prodrug 7 against E. coli MG1655 







Figure 5-10. Percent P. falciparum killed with IDP rescue as a function of drug 
concentration. The dose response shown in blue for: A) fosmidomycin, B) FR900098, 
C) compound 6, and D) compound 7. Rescue by IDP is shown in red. 
 
Conclusions 
In this chapter we present alternatives to facilitate the intracellular entry of 
fosmidomycin and its analogs, toward improving pharmacokinetic propoerties. This was 
achieved by 1) taking advantage of the “two part” substrate mechanism that was recently 
elucidated for IspC 
(16)
 in which the dianion drives conformational changes of the active 
site, and 2) employing a prodrug strategy requiring intracellular phosphorylation of a 
hydroxyethyl precursor to fosfoxacin, and 3) using a phosphoamidite prodrug strategy for 
intracellular delivery of phosphonylated FR900098 
(17-21)
. We show that acetohydroxamic 




is an important finding because estimates of intracellular phosphate concentration are on 
the same order of magnitude as what is required to synergistically inhibit IspC in 
combination with AHA. Acetohydroxamic acid (AHA, 3) is a potent and irreversible 
inhibitor of bacterial and plant urease 
(27)
. Also known as Lithostat, it is used as an 
antibiotic to treat urinary tract infections 
(27)
.  Further, AHA is already an FDA approved 
antibiotic for the treatment of urinary tract infections, so it is possible that in addition to 
targeting bacterial urease, it might also act in combination with intracellular phosphate 
anion to inhibit IspC. 
Additionally, we examined compound 7 as a prodrug of FR900098. As expected, 
compound 7, bearing the masked phosphonyl group, does not inhibit recombinant E. coli 
IspC in vitro (IC50 > 0.5 mM); however, upon prodrug activation in the presence of E. 
coli nitroreductase, inhibition of IspC is indeed observed at a comparable activity to 
FR900098 under the same conditions (IC50
apparent
 = 0.27 ± 0.09 µM). This suggests that 
reduction of 7 leads to the expulsion of the active inhibitor. Importantly, prodrug 7 
possesses potent anti-parasitic activity (EC50 = 1.0 ± 0.07 µM) that is rescued in the 
presence of IDP, suggesting prodrug 7 undergoes intracellular activation to release 




General Methods. Unless otherwise noted, all reagents were obtained from commercial 
sources. E. coli wild type DXP synthase was purified as described previously 
(28)
. E. coli 
DXP reductoisomerase (IspC) was also prepared as described previously 
(29)




purchased from Sigma. All other fosmidomycin/FR900098 analogs were chemically 
synthesized by Dr. David Meyers, Synthetic Core Facility. 
 
Kinetic Analyses. DXP was generated using E. coli DXP synthase. DXP synthase 
reaction mixtures containing HEPES (100 mM, pH 8.0), 1 mg/mL BSA, 2 mM MgCl2, 
2.5 mM tris(2-carboxyethyl)phosphine, 1 mM ThDP, 4 mM D,L-GAP, and 4 mM 
pyruvate were incubated at 37 °C for 90 minutes until reaction completion. After 
completion, DXP concentration was determined in a reaction mixture containing:  
HEPES (100 mM, pH 8.0), 1 mg/mL BSA, 2 mM MgCl2, 0.1 mM nicotinamide adenine 
dinucleotide phosphate (NAPDH), and 0.5 µM IspC. The final concentration of NAPDH 
was recorded at 340 nm and the concentration of DXP was determined. IspC was 
kinetically characterized as previously reported 
(29)
, with minor modifications: 10 nM 
enzyme was added to initiate each reaction, and the rate of NADPH depletion was 
monitored spectrophotometrically at 340 nm at 37°C. When NAPDH was the varied 
substrate, DXP was fixed at 0.5 mM. When DXP was the varied substrate, NAPDH was 
held at 0.1 mM. Double reciprocal analysis was performed using GraFit from Erithacus 
Software (version 7). 
 
Inhibition Studies. IspC reaction mixtures were prepared as described above, with 0.18 
mM NAPDH, 0.14 mM DXP, and 50 nM IspC. For inhibition assays, fosmidomycin was 
varied from 0 - 0.75 µM, compounds 4 – 7 were varied from 0 – 10 mM. The rate of IspC 
was also evaluated in the presence of chloride, bicarbonate, inorganic phosphate, and 




mM sodium chloride (NaCl), 5 mM bicarbonate, 5 mM inorganic phosphate, and 0.25 
µM diphosphate. Activation period of prodrug 7 was carried out over 6 hours, at 37 °C 
with the following reaction conditions: 100 mM HEPES (pH = 8.0), 0.25 mM NADH, 
0.25 µM E. coli nitroreductase, and 0.25 mM prodrug 7. 
 
Evaluation of IspC inhibitors against E. coli and P. falciparum. Prodrug 7 was 
evaluated against E. coli MG1655 as outlined in Chapter 4. Evaluation of compounds 3 - 
7 against P. falciparum was carried out as previously reported 
(30)
, in medium 
supplemented with either 10% O
+
 serum or Albumax II, a serum substitute. 
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